0001683168-24-003175.txt : 20240509 0001683168-24-003175.hdr.sgml : 20240509 20240509172056 ACCESSION NUMBER: 0001683168-24-003175 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Phio Pharmaceuticals Corp. CENTRAL INDEX KEY: 0001533040 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36304 FILM NUMBER: 24931976 BUSINESS ADDRESS: STREET 1: 11 APEX DRIVE, SUITE 300A STREET 2: PMB 2006 CITY: MARLBOROUGH STATE: MA ZIP: 01752 BUSINESS PHONE: (508) 767-3861 MAIL ADDRESS: STREET 1: 11 APEX DRIVE, SUITE 300A STREET 2: PMB 2006 CITY: MARLBOROUGH STATE: MA ZIP: 01752 FORMER COMPANY: FORMER CONFORMED NAME: RXi Pharmaceuticals Corp DATE OF NAME CHANGE: 20111019 10-Q 1 phio_i10q-033124.htm FORM 10-Q FOR 3/31/24 Phio Pharmaceuticals Corp. 10-Q
false --12-31 2024 Q1 0001533040 0001533040 2024-01-01 2024-03-31 0001533040 2024-05-03 0001533040 2024-03-31 0001533040 2023-12-31 0001533040 2023-01-01 2023-03-31 0001533040 phio:PreferredStockSeriesDMember 2023-12-31 0001533040 us-gaap:CommonStockMember 2023-12-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001533040 us-gaap:RetainedEarningsMember 2023-12-31 0001533040 phio:PreferredStockSeriesDMember 2022-12-31 0001533040 us-gaap:CommonStockMember 2022-12-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001533040 us-gaap:RetainedEarningsMember 2022-12-31 0001533040 2022-12-31 0001533040 phio:PreferredStockSeriesDMember 2024-01-01 2024-03-31 0001533040 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001533040 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001533040 phio:PreferredStockSeriesDMember 2023-01-01 2023-03-31 0001533040 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001533040 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001533040 phio:PreferredStockSeriesDMember 2024-03-31 0001533040 us-gaap:CommonStockMember 2024-03-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001533040 us-gaap:RetainedEarningsMember 2024-03-31 0001533040 phio:PreferredStockSeriesDMember 2023-03-31 0001533040 us-gaap:CommonStockMember 2023-03-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001533040 us-gaap:RetainedEarningsMember 2023-03-31 0001533040 2023-03-31 0001533040 phio:ClinicalCoDevelopmentAgreementMember phio:AgonOxMember 2024-01-01 2024-03-31 0001533040 phio:ClinicalCoDevelopmentAgreementMember phio:AgonOxMember 2023-01-01 2023-03-31 0001533040 phio:ClinicalCoDevelopmentAgreementMember phio:AgonOxMember 2023-12-31 0001533040 us-gaap:CashAndCashEquivalentsMember 2024-03-31 0001533040 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2024-03-31 0001533040 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2024-03-31 0001533040 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2024-03-31 0001533040 us-gaap:FairValueInputsLevel1Member 2024-03-31 0001533040 us-gaap:FairValueInputsLevel2Member 2024-03-31 0001533040 us-gaap:FairValueInputsLevel3Member 2024-03-31 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember 2024-03-31 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember 2024-01-01 2024-03-31 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember 2024-03-01 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember 2024-02-29 2024-03-01 0001533040 phio:December2023FinancingMember 2023-01-01 2023-12-31 0001533040 phio:AbeyanceSharesMember 2023-12-31 0001533040 us-gaap:WarrantMember 2023-12-31 0001533040 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001533040 us-gaap:WarrantMember 2024-03-31 0001533040 us-gaap:RestrictedStockUnitsRSUMember phio:EmployeesMember 2024-01-01 2024-03-31 0001533040 us-gaap:RestrictedStockUnitsRSUMember phio:NonEmployeeMembersMember 2024-01-01 2024-03-31 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001533040 us-gaap:EmployeeStockOptionMember phio:EmployeesMember 2024-01-01 2024-03-31 0001533040 us-gaap:EmployeeStockOptionMember phio:BoardOfDirectorsMember 2024-01-01 2024-03-31 0001533040 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001533040 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001533040 us-gaap:EmployeeStockOptionMember 2023-12-31 0001533040 us-gaap:EmployeeStockOptionMember 2024-03-31 0001533040 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001533040 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001533040 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001533040 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001533040 phio:StockOptionsMember 2024-01-01 2024-03-31 0001533040 phio:StockOptionsMember 2023-01-01 2023-03-31 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001533040 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001533040 us-gaap:WarrantMember 2023-01-01 2023-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2024

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                  to                  

 

Commission File Number: 001-36304

 

Phio Pharmaceuticals Corp.

(Exact name of registrant as specified in its charter)

 

Delaware 45-3215903
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

 

11 Apex Drive, Suite 300A, PMB 2006, Marlborough, MA 01752

(Address of principal executive office) (Zip code)

 

Registrant’s telephone number, including area code: (508) 767-3861

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value, $0.0001 per share PHIO The Nasdaq Capital Market

  

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

  

Large accelerated filer   ☐   Accelerated filer   ☐
Non-accelerated filer   ☒   Smaller reporting company   ☒
        Emerging growth company   ☐

  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of May 3, 2024, Phio Pharmaceuticals Corp. had 4,591,700 shares of common stock, $0.0001 par value, outstanding.

 

 

 

 

   

 

 

PHIO PHARMACEUTICALS CORP.

FORM 10-Q — QUARTER ENDED MARCH 31, 2024

 

INDEX

 

Part No.   Item No.   Description   Page
No.
             
I       FINANCIAL INFORMATION   3
             
    1   Financial Statements (Unaudited)   3
        Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023   3
        Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2024 and 2023   4
        Condensed Consolidated Statements of Preferred Stock and Stockholders’ Equity for the Three Months Ended March 31, 2024 and 2023   5
        Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023   6
        Notes to Condensed Consolidated Financial Statements   7
    2   Management’s Discussion and Analysis of Financial Condition and Results of Operations   14
    3   Quantitative and Qualitative Disclosures About Market Risk   18
    4   Controls and Procedures   18
             
II       OTHER INFORMATION   19
             
    1   Legal Proceedings   19
    1A   Risk Factors   19
    2   Unregistered Sales of Equity Securities and Use of Proceeds   20
    3   Defaults Upon Senior Securities   20
    4   Mine Safety Disclosures   20
    5   Other Information   20
    6   Exhibits   22
             
Signatures   23

 

 

 

 

 

 2 

 

 

PART I — FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

PHIO PHARMACEUTICALS CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except share and per share data)

(Unaudited)

 

         
   March 31,
2024		   December 31,
2023		 
ASSETS          
Current assets:          
Cash and cash equivalents  $6,475   $8,490 
Prepaid expenses and other current assets   373    832 
Total current assets   6,848    9,322 
Right of use asset   –    33 
Property and equipment, net   2    6 
Other assets   3    3 
Total assets  $6,853   $9,364 
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $320   $657 
Accrued expenses   929    942 
Lease liability   –    35 
Total current liabilities   1,249    1,634 
Commitments and contingencies (Note 2)   –    – 
Stockholders’ equity:          
Preferred stock, $0.0001 par value, 100,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively   –    – 
Common stock, $0.0001 par value, 100,000,000 shares authorized; 4,591,700 and 3,747,329 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively   –    – 
Additional paid-in capital   146,964    146,936 
Accumulated deficit   (141,360)   (139,206)
Total stockholders’ equity   5,604    7,730 
Total liabilities and stockholders’ equity  $6,853   $9,364 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

 3 

 

 

PHIO PHARMACEUTICALS CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except share and per share data)

(Unaudited)

 

         
  

Three Months

Ended March 31,

 
   2024   2023 
Operating expenses:          
Research and development  $1,148   $2,134 
General and administrative   1,061    1,468 
Total operating expenses   2,209    3,602 
Operating loss   (2,209)   (3,602)
Total other income, net   55    – 
Net loss  $(2,154)  $(3,602)
Net loss per common share:          
Basic and diluted  $(0.47)  $(3.15)
Weighted average number of common shares outstanding:          
Basic and diluted   4,580,072    1,142,213 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

 

 

 

 

 

 

 

 

 4 

 

 

PHIO PHARMACEUTICALS CORP.

CONDENSED CONSOLIDATED STATEMENTS OF

PREFERRED STOCK AND STOCKHOLDERS’ EQUITY

(Amounts in thousands, except share data)

(Unaudited)

 

                             
   Series D Preferred Stock   Common Stock   Additional
Paid-in		   Accumulated     
For the Three Months Ended March 31, 2024  Shares   Amount   Shares   Amount   Capital   Deficit   Total 
Balance at December 31, 2023   –   $–    3,747,329   $–   $146,936   $(139,206)  $7,730 
Issuance of common stock upon exercise of warrants   –    –    826,370    –    –    –    – 
Issuance of common stock upon vesting of restricted stock units   –    –    24,198    –    –    –    – 
Shares withheld for payroll taxes   –    –    (6,197)   –    (4)   –    (4)
Stock-based compensation expense   –    –    –    –    32    –    32 
Net loss   –    –    –    –    –    (2,154)   (2,154)
Balance at March 31, 2024   –   $–    4,591,700   $–   $146,964   $(141,360)  $5,604 

 

                             
   Series D Preferred Stock   Common Stock   Additional
Paid-in		   Accumulated     
For the Three Months Ended March 31, 2023  Shares   Amount   Shares   Amount   Capital   Deficit   Total 
Balance at December 31, 2022   1   $2    1,139,024   $–   $139,218   $(128,380)  $10,838 
Cash-in-lieu of fractional shares for reverse stock split   –    –    (1,706)   –    (11)   –    (11)
Redemption of preferred stock   (1)   (2)   –    –    –    –    – 
Issuance of common stock upon vesting of restricted stock units   –    –    18,080    –    –    –    – 
Shares withheld for payroll taxes   –    –    (4,816)   –    (25)   –    (25)
Stock-based compensation expense   –    –    –    –    111    –    111 
Net loss   –    –    –    –    –    (3,602)   (3,602)
Balance at March 31, 2023   –   $–    1,150,582   $–   $139,293   $(131,982)  $7,311 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

 

 

 

 

 5 

 

 

PHIO PHARMACEUTICALS CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands)
(Unaudited)

 

           
  

Three Months Ended

March 31,

 
   2024   2023 
Cash flows from operating activities:          
Net loss  $(2,154)  $(3,602)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   1    16 
Amortization of right of use asset   33    31 
Loss on disposal of property and equipment   3    – 
Stock-based compensation   32    111 
Changes in operating assets and liabilities:          
Prepaid expenses and other assets   459    314 
Accounts payable   (337)   123 
Accrued expenses   (13)   331 
Lease liability   (35)   (32)
Net cash used in operating activities   (2,011)   (2,708)
Cash flows from financing activities:          
Cash in lieu of fractional shares for reverse stock split   –    (11)
Redemption of Series D preferred stock   –    (2)
Payment of taxes on net share settlements of restricted stock units   (4)   (25)
Net cash used in financing activities   (4)   (38)
Net decrease in cash, cash equivalents and restricted cash   (2,015)   (2,746)
Cash, cash equivalents and restricted cash at the beginning of period   8,490    11,831 
Cash, cash equivalents and restricted cash at the end of period  $6,475   $9,085 

 

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the totals above:

         
   March 31, 
   2024   2023 
Cash and cash equivalents  $6,475   $9,035 
Restricted cash   –    50 
Cash, cash equivalents and restricted cash  $6,475   $9,085 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

 

 

 

 

 6 

 

 

PHIO PHARMACEUTICALS CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

 

1. Organization and Significant Accounting Policies

 

Nature of Operations

 

Phio Pharmaceuticals Corp. (“Phio” or the “Company”) is a clinical stage biotechnology company whose proprietary INTASYL™ small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.

 

Phio was incorporated in the state of Delaware in 2011 as RXi Pharmaceuticals Corporation. On November 19, 2018, the Company changed its name to Phio Pharmaceuticals Corp., to reflect its transition from a platform company to one that is fully committed to developing groundbreaking immuno-oncology therapeutics.

 

Basis of Presentation

 

The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Certain information and footnote disclosures that are included in the Company’s annual consolidated financial statements, but that are not required for interim reporting purposes, have been condensed or omitted. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included.

 

These statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024 (the “2023 Form 10-K”). Interim results are not necessarily indicative of results for a full year.

 

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, MirImmune, LLC. All material intercompany accounts have been eliminated in consolidation.

 

Segments

 

The Company operates as one operating segment and all assets are located in the United States.

 

Use of Estimates

 

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas subject to significant estimates and judgement include, among others, those related to the fair value of equity awards, accruals for research and development expenses, useful lives of property and equipment, and the valuation allowance on the Company’s deferred tax assets. On an ongoing basis the Company evaluates its estimates and bases its estimates on historical experience and other relevant assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from these estimates.

 

 

 

 7 

 

 

Liquidity

 

The Company has reported recurring losses from operations since its inception and expects to continue to have negative cash flows from operations for the foreseeable future. Historically, the Company’s primary source of funding has been from sales of its securities. The Company’s ability to continue to fund its operations is dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, or strategic opportunities, in order to maintain its operations. This is dependent on a number of factors, including the market demand or liquidity of the Company’s common stock. There is no guarantee that debt, additional equity or other funding will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, the Company would be forced to scale back or terminate its operations or seek to merge with or to be acquired by another company.

 

The Company has limited cash resources, has reported recurring losses from operations since inception, has negative operating cash flows and has not yet received product revenues. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern, and the Company’s current cash resources may not provide sufficient capital to fund operations for at least the next 12 months from the date of the release of these condensed consolidated financial statements. The continuation of the Company as a going concern depends upon the Company’s ability to raise additional capital through an equity offering, debt offering and/or strategic opportunity to fund its operations. There can be no assurance that the Company will be successful in accomplishing these plans in order to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Summary of Significant Accounting Policies

 

Cash and Cash Equivalents

 

Cash and cash equivalents include unrestricted cash accounts, money market investments and highly liquid investment instruments with original maturity of three months or less at the date of purchase.

 

Other than as set forth above, there have been no material changes to the significant accounting policies disclosed in the Company’s 2023 Form 10-K.

 

Recent Accounting Pronouncements

 

In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting (Topic 280) – Improvements to Reporting Segment Disclosures” (“ASU 2023-07”), which requires disclosure of incremental segment information on an annual and interim basis. In addition, ASU 2023-07 clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and contains other disclosure requirements. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The enhanced disclosures are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of ASU 2023-07 on its consolidated financial statements and disclosures, but does not expect that it will have a material impact on its consolidated financial statements.

 

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740) – Improvements to Income Tax Disclosures” (“ASU 2023-09”), which requires disclosure of specific categories in the rate reconciliation table along with additional information for reconciling items that meet a quantitative threshold, disclosure of disaggregated income taxes paid and modifies other income tax-related disclosures. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-09, but does not expect that it will have a material impact on its consolidated financial statements.

 

 

 

 8 

 

 

2. Collaboration Agreement

 

AgonOx, Inc. (“AgonOx”)

 

In February 2021, the Company entered into a clinical co-development collaboration agreement (the “Clinical Co-Development Agreement”) with AgonOx, a private company developing a pipeline of novel immunotherapy drugs targeting key regulators of the immune response to cancer. Under the Clinical Co-Development Agreement, Phio and AgonOx are working to develop a T cell-based therapy using the Company’s lead product candidate, PH-762, and AgonOx’s “double positive” tumor infiltrating lymphocytes (“DP TIL”) technology. Per the terms of the Clinical Co-Development Agreement, the Company agreed to reimburse AgonOx up to $4,000,000 in expenses incurred to conduct a Phase 1 clinical trial of PH-762 treated DP TIL in patients with advanced melanoma and other advanced solid tumors.

 

The Company recognizes its share of costs arising from research and development activities performed by AgonOx in the Company’s condensed consolidated financial statements in the period AgonOx incurs such expense. Phio will be entitled to certain future development milestones and low single-digit sales-based royalty payments from AgonOx’s licensing of its DP TIL technology.

 

The Company recognized approximately $50,000 and $119,000 of expense in connection with these efforts during the three months ended March 31, 2024 and 2023, respectively.

 

On May 8, 2024, the Company terminated its Clinical Co-Development Agreement with AgonOx, effective immediately. Effective as of the date of the termination, the Clinical Co-Development Agreement and the continuing obligations of the Company and AgonOx thereunder will be terminated in their entirety. The Company will no longer be required to provide financial support for the development costs incurred under the Clinical Co-Development Agreement or be entitled to certain future development milestones and low single-digit sales-based royalty payments from AgonOx’s licensing of its DP TIL technology.

 

The Company will pay to AgonOx all Company payment obligations that have accrued prior to the termination of the Clinical Co-Development Agreement. The Company intends to pay to AgonOx future fees to be incurred for patients that were treated in the Phase 1 clinical trial as of the date of termination. The Company estimates that such payments to be made to AgonOx will amount to approximately $388,000, which primarily relate to the Company’s accrued obligations under the Clinical Co-Development Agreement as of March 31, 2024, as well as future fees to be incurred for patients that were treated in the Phase 1 clinical trial and other miscellaneous costs as of the date of termination. Pursuant to the terms of the Clinical Co-Development Agreement, the Company and AgonOx shall meet and discuss the orderly wind-down of the Phase 1 clinical trial. Each of the Company and AgonOx shall be responsible for its own costs and expenses incurred in connection with the wind-down of the Phase 1 clinical trial. See Item 5. Other Information included elsewhere in this Quarterly Report for further information.

 

3. Fair Value of Financial Instruments

 

The Company follows the provisions of the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 820, “Fair Value Measurement,” for the Company’s financial assets and liabilities that are re-measured and reported at fair value each reporting period and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:

 

Level 1 – quoted prices in active markets for identical assets or liabilities.

 

Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

 

Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

 

As of March 31, 2024, the Company categorized its cash equivalents as Level 1 hierarchy as the carrying amounts approximate their fair value due to their short-term nature and market rates of interest. As of December 31, 2023, the Company did not identify any financial instruments required to be presented at fair value.

                    
Description  March 31, 2024  

Quoted Prices

In Active Markets
(Level 1)

    Other Significant
Observable Inputs
(Level 2)		   Unobservable
Inputs
(Level 3)		 
Assets:                    
Cash equivalents  $6,379   $6,379   $–   $– 
Total  $6,379   $6,379   $–   $– 

 

The carrying amounts of cash, accounts payable and accrued expenses of the Company approximate their fair values due to their short-term nature.

 

 

 9 

 

 

4. Leases

 

The Company’s lease for its corporate headquarters and primary research facility in Marlborough, Massachusetts was for a total of 7,581 square feet of office and laboratory space and expired on March 31, 2024. The lease agreement did not contain information to determine the borrowing rate implicit in the lease. As such, the Company calculated its incremental borrowing rate based on what the Company would have to pay to borrow on a collateralized basis over the lease term for an amount equal to the remaining lease payments, taking into consideration such assumptions as, but not limited to, the U.S. treasury yield rate and borrowing rates from a creditworthy financial institution using the above lease factors. The Company has continued operations as a primarily remote business with the expiration of the lease, but has contracted a private mailbox with an address of 11 Apex Drive, Suite 300A, PMB 2006, Marlborough, MA 01752 to use as its principal mailing address for SEC and other purposes.

 

The Company entered into a lease for a laboratory facility located at 17 Briden Street, Worcester, Massachusetts, which commenced on March 1, 2024. The lease covers 321 square feet of rentable space and expires on September 1, 2024. The total base rent for the premises over the term is expected to be $15,000 and the Company has the option to renew for additional 6-month periods. The Company made an accounting policy election under the FASB ASC Topic 824, “Leases” not to recognize leases with a term less than one year on the balance sheet and that do not contain a purchase option. Under the short-term lease election, the Company will recognize the lease payments for the laboratory facility on a straight-line basis over the lease term.

 

The lease for the Company’s corporate headquarters represented all of our significant lease obligations.

 

The amounts reported in the condensed consolidated balance sheets for the Company’s corporate headquarters classified as an operating lease in which the Company is the lessee and other supplemental balance sheet information is set forth as follows, in thousands, except the lease term (number of years) and discount rate:

        
   March 31, 2024   December 31, 2023 
Assets          
Right of use asset  $–   $33 
Liabilities          
Lease liability  $–   $35 
Lease Term and Discount Rate          
Weighted average remaining lease term   –    0.25 
Weighted average discount rate   4.70%    4.70% 

 

Operating lease costs included in operating expense were $33,000 for the three months ended March 31, 2024 and 2023, respectively.

  

Cash paid for the amounts included in the measurement of the operating lease liability on the Company’s condensed consolidated balance sheets and included within changes in the lease liability in the operating activities of the Company’s condensed consolidated statements of cash flows was $35,000 and $34,000 for the three months ended March 31, 2024 and 2023, respectively.

 

 

 

 

 10 

 

 

5. Stockholders’ Equity

 

Warrants

 

The Company first assesses warrants that are issued by the Company under the FASB ASC Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”) to determine whether the warrants are within the scope of ASC 480. If there are no instances outside of the Company’s control that could require cash settlement, the Company then applies and follows the applicable accounting guidance in the FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). Financial instruments are accounted for as either derivative liabilities or equity instruments depending on the specific terms of the agreement. Based on the assessment of the warrants issued by the Company under the guidance in ASC 480 and ASC 815, the warrants issued by the Company have been classified within stockholder’s equity.

 

In December 2023, the Company entered into an inducement letter agreement (the “Inducement Letter Agreement”) with certain holders of the Company’s existing warrants to purchase up to an aggregate of 2,130,252 shares of the Company’s common stock (the “December 2023 Financing”). Pursuant to the terms of the Inducement Letter Agreement, in the event that the exercise of the existing warrants in the December 2023 Financing would have otherwise caused a holder to exceed the beneficial ownership limitations set forth in the existing warrant, the Company issued the number of shares that would not cause a holder to exceed such beneficial ownership limitation and agreed to hold such balance of shares of common stock in abeyance. Accordingly, an aggregate of 826,370 shares of common stock were held in abeyance (the “Abeyance Shares”) with such Abeyance Shares evidenced through the holder’s existing warrants and which were deemed to be prepaid. The Abeyance Shares were held until notice was received by the holder that the balance of the shares of common stock could be issued in compliance with such beneficial ownership limitations and were exercised pursuant to a notice of exercise from the holder. Until such time, the Abeyance Shares were evidenced through the holder’s existing warrants and have been included in the Company’s table of outstanding warrants below.

 

During the three months ended March 31, 2024, all of the Abeyance Shares were released and issued. There were no warrant exercises during the three months ended March 31, 2023.

 

The following table summarizes the Company’s outstanding warrants, all of which are classified as equity instruments, at March 31, 2024:

          
    Number
of Shares		   Weighted-
Average
Exercise Price
Per Share		 
Outstanding at December 31, 2023   6,331,288   $3.68 
Issued   –    – 
Exercised   (826,370)   1.33 
Expired   –    – 
Outstanding at March 31, 2024   5,504,918   $4.03 

 

6. Stock-based Compensation

 

Restricted Stock Units

 

Restricted stock units (“RSUs”) are issued under the Company’s 2020 Long-Term Incentive Plan (the “2020 Plan”) or as inducement grants issued outside of the 2020 Plan to new employees. RSUs are generally subject to graded vesting and the satisfaction of certain service requirements. RSUs granted by the Company to employees generally vest annually over 3 years after the grant date and over 1 year after the grant date for non-employee members of the Board of Directors. Upon vesting, each outstanding RSU will be settled for one share of the Company’s common stock. Employee RSU recipients may elect to net share settle upon vesting, in which case the Company pays the employee’s income taxes due upon vesting and withholds a number of shares of equal value. The Company does not expect to repurchase shares to satisfy RSU vests. The fair value of the RSUs awarded are based upon the Company’s closing stock price at the grant date and are expensed over the requisite service period.

 

 

 

 

 11 

 

 

The following table summarizes the activity of the Company’s RSUs for the three months ended March 31, 2024:

          
   Number
of Shares		   Weighted-
Average
Grant Date Fair Value
Per Share		 
Unvested units at December 31, 2023   49,683   $8.32 
Granted   –    – 
Vested   (24,198)   8.80 
Forfeited   (6,903)   10.96 
Unvested units at March 31, 2024   18,582   $6.70 

 

There were no RSUs granted during the three months ended March 31, 2024. The weighted-average fair value of RSUs granted during the three months ended March 31, 2023 was $5.24.

  

Stock-based compensation expense related to RSUs was $26,000 and $111,000 for the three months ended March 31, 2024 and 2023, respectively.

 

The aggregate fair value of awards that vested during the three months ended March 31, 2024 and 2023 was $17,000 and $95,000, respectively, which represents the market value of the Company’s common stock on the date that the RSUs vested.

 

Stock Options

 

Stock options are available for issuance under the 2020 Plan or as inducement grants issued outside of the 2020 Plan to new employees. Stock options are generally subject to graded vesting and the satisfaction of service requirements. Stock options granted by the Company to employees generally vest annually over 4 years after the grant date and generally vest over 1 year after the grant date for members of the Board of Directors and expire within ten years of grant. Upon the exercise of a stock option, the Company issues new shares and delivers them to the recipient. The Company does not expect to repurchase shares to satisfy stock option exercises.

 

The Company uses the Black-Scholes option-pricing model to determine the fair value of all its option grants. The risk-free interest rate used for each grant was based upon the yield on zero-coupon U.S. Treasury securities with a term similar to the expected life of the related option. The Company’s expected stock price volatility assumption is based upon the Company’s own implied volatility. As the Company has limited stock option exercise information, the expected life assumption used for option grants is based upon the simplified method provided for under the FASB ASC Topic 718, “Compensation — Stock Compensation”. The dividend yield assumption is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends.

 

The Company did not grant any stock options during the three months ended March 31, 2024 and 2023.

 

The following table summarizes the activity of the Company’s stock options for the three months ended March 31, 2024:

               
   Number
of Shares		   Weighted-
Average
Exercise
Price
Per Share		   Aggregate
Intrinsic
Value		 
Balance at December 31, 2023   10,084   $134.86      
Granted   –    –      
Exercised   –    –      
Forfeited   –    –      
Expired   (23)   13,541.48      
Balance at March 31, 2024   10,061   $104.21   $– 
Exercisable at March 31, 2024   10,061   $104.21   $– 

 

Stock-based compensation expense related to stock options for the three months ended March 31, 2024 was $6,000. The Company did not have any stock-based compensation expense related to stock options for the three months ended March 31, 2023.

 

 

 

 12 

 

 

Compensation Expense Related to Equity Awards

 

The following table sets forth total stock-based compensation expense for the three months ended March 31, 2024 and 2023, in thousands:

          
   March 31, 
   2024   2023 
Research and development  $(11)  $63 
General and administrative   43    48 
Total stock-based compensation  $32   $111 

 

7. Net Loss per Common Share

 

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing the Company’s net loss by the weighted average number of common shares outstanding and the impact of the dilutive effect of potential common stock equivalents, except when the inclusion of such potential common stock equivalents would be anti-dilutive. Dilutive potential common stock equivalents primarily consist of stock options, RSUs and warrants. Therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented because the impact of these items is generally anti-dilutive during periods of net loss.

 

The following table sets forth the potential common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:

          
   March 31, 
   2024   2023 
Stock options   10,061    177 
Unvested RSUs   18,582    72,755 
Warrants   5,504,918    545,401 
Total   5,533,561    618,333 

 

 

 

 

 

 

 13 

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

In this report, “we,” “our,” “ours,” “us,” “Phio” and the “Company” refers to Phio Pharmaceuticals Corp. and our subsidiary, MirImmune, LLC and the ongoing business operations of Phio Pharmaceuticals Corp. and MirImmune, LLC, whether conducted through Phio Pharmaceuticals Corp. or MirImmune, LLC.

 

This management’s discussion and analysis of financial condition as of March 31, 2024 and results of operations for the three months ended March 31, 2024 and 2023 should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024 (the “2023 Form 10-K”).

 

This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “intends,” “believes,” “anticipates,” “indicates,” “plans,” “expects,” “suggests,” “may,” “would,” “should,” “potential,” “designed to,” “will,” “ongoing,” “estimate,” “forecast,” “target,” “predict,” “could” and similar references, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Risks that could cause actual results to vary from expected results expressed in our forward-looking statements include, but are not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, if any, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, results from our preclinical and clinical activities, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, and our ability to obtain future financing. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including those identified in our 2023 Form 10-K under the heading “Risk Factors” and in other filings the Company periodically makes with the SEC. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q speak as of the date hereof and the Company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this report except as required by law.

 

Overview

 

Phio is a clinical stage biotechnology company whose proprietary INTASYL™ small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. We are developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.

 

Cost Rationalization

 

In 2023, we implemented a cost rationalization program driven by our transition from a research company to a product development company. This transition resulted in a decision not to renew the lease for our corporate headquarters and primary research facility in Marlborough, Massachusetts, which expired on March 31, 2024. As of April 1, 2024, we have continued operations primarily as a remote business with a laboratory facility in Worcester, Massachusetts. Additionally, we rationalized research personnel and reduced our headcount by approximately 36%. These expense reductions have been redirected to funding the Phase 1b clinical trial with PH-762 directed toward skin cancer.

 

 

 

 14 

 

 

PH-762

 

PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (“PD-1”). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. Decreasing the expression of PD-1 can thereby increase the capacity of T cells, which protect the body from cancer cells and infections, to kill cancer cells.

 

Our preclinical studies have demonstrated that direct-to-tumor application of PH-762 resulted in potent anti-tumoral effects and have shown that direct-to-tumor treatment with PH-762 inhibits tumor growth in a dose dependent fashion in PD-1 responsive and refractory models. Importantly, direct-to-tumor administration of PH-762 resulted in activity against distant untreated tumors, indicative of a systemic anti-tumor response. We believe these data further support the potential for PH-762 to provide a strong local immune response without the dose immune-related adverse effects seen with systemic antibody therapy.

 

PH-762 is currently being evaluated in a U.S. multi-center Phase 1b dose-escalating clinical trial through the intratumoral injection of PH-762 for the treatment of patients with cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. The trial is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose or dose range for continued study of PH-762 and is expected to enroll up to 30 patients. In November 2023, we announced the dosing of the first patient under a previously cleared Investigational New Drug (“IND”) application by the U.S. Food and Drug Administration. The first two patients enrolled in our first cohort have completed treatment with PH-762 with no reported adverse events. The trial is currently open for the continued enrollment of patients and expects to complete enrollment of patients in the second quarter of 2025.

 

AgonOx Collaboration

 

Due to INTASYL’s ease of administration, we have shown that our compounds can easily be incorporated into current adoptive cell therapy (“ACT”) manufacturing processes. In ACT, T cells are usually taken from a patient's own blood or tumor tissue, grown in large numbers in a laboratory, and then given back to the patient to help the immune system fight cancer. By treating T cells with our INTASYL compounds while they are being grown in the laboratory, we believe our INTASYL compounds can improve these immune cells to make them more effective in killing cancer. Preclinical data generated in collaboration with AgonOx, Inc. (“AgonOx”), a private company developing a pipeline of novel immunotherapy drugs targeting key regulators of the immune response to cancer, demonstrated that treating AgonOx’s “double positive” tumor infiltrating lymphocytes (“DP TIL”) with PH-762 increased their tumor killing activity by two-fold.

 

In February 2021, we entered into a clinical co-development collaboration agreement (the “Clinical Co-Development Agreement”) with AgonOx to develop a T cell-based therapy using PH-762 and AgonOx’s DP TIL. Under the Clinical Co-Development Agreement, we had agreed to reimburse AgonOx up to $4 million in expenses incurred to conduct a Phase 1 clinical trial of PH-762 treated DP TIL in patients with advanced melanoma and other advanced solid tumors. We were also eligible to receive certain future development milestones and low single-digit sales-based royalty payments from AgonOx’s licensing of its DP TIL technology.

 

On May 8, 2024, we terminated the Clinical Co-Development Agreement with AgonOx, effective immediately. Effective as of the date of the termination, the Clinical Co-Development Agreement and our continuing obligations and those of AgonOx thereunder will be terminated in their entirety. We will no longer be required to provide financial support for the development costs incurred under the Clinical Co-Development Agreement or be entitled to certain future development milestones and low single-digit sales-based royalty payments from AgonOx’s licensing of its DP TIL technology. We will pay to AgonOx all payment obligations that have accrued prior to the termination of the Clinical Co-Development Agreement. We intend to pay to AgonOx future fees to be incurred for patients that were treated in the Phase 1 clinical trial as of the date of termination. We estimate that such payments to be made to AgonOx will amount to approximately $388,000, which primarily relate to our accrued obligations under the Clinical Co-Development Agreement as of March 31, 2024, as well as future fees to be incurred for patients that were treated in the Phase 1 clinical trial and other miscellaneous costs as of the date of termination. Pursuant to the terms of the Clinical Co-Development Agreement, we and AgonOx shall meet and discuss the orderly wind-down of the Phase 1 clinical trial. Each of us and AgonOx shall be responsible for its own costs and expenses incurred in connection with the wind-down of the Phase 1 clinical trial. See Item 5. Other Information included elsewhere in this Quarterly Report for further information.

 

Prior to the termination of the Clinical Co-Development Agreement with AgonOx, PH-762 treated DP TIL were being evaluated in a Phase 1 clinical trial in the United States with up to 18 patients with advanced melanoma and other advanced solid tumors by AgonOx. The primary trial objectives were to evaluate the safety and to study the potential for enhanced therapeutic benefit from the administration of PH-762 treated DP TIL. AgonOx had enrolled three patients. The first two patients were treated with DP TIL only and the third patient was treated with a combination of DP TIL and PH-762.

 

 

 

 

 15 

 

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates and base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions and could have a material impact on our reported results.

 

There have been no material changes to our critical accounting policies and estimates as compared to those disclosed in our 2023 Form 10-K.

 

Results of Operations

 

The following data summarizes the results of our operations for the periods indicated, in thousands: 

 

   Three Months Ended
March 31,		   Dollar 
   2024   2023   Change 
Operating expenses  $2,209   $3,602   $(1,393)
Operating loss  $(2,209)  $(3,602)  $1,393 
Net loss  $(2,154)  $(3,602)  $1,448 

 

Comparison of the Three Months Ended March 31, 2024 and 2023

 

Operating Expenses

 

The following table summarizes our total operating expenses, for the periods indicated, in thousands:

 

   Three Months Ended
March 31,		   Dollar 
   2024   2023   Change 
Research and development  $1,148   $2,134   $(986)
General and administrative   1,061    1,468    (407)
Total operating expenses  $2,209   $3,602   $(1,393)

 

Research and Development Expenses

 

Research and development expenses relate to compensation and benefits for research and development personnel, facility-related expenses, supplies, external services, costs to acquire technology licenses, research activities under our research collaboration agreement, expenses associated with preclinical and clinical development activities and other operating costs. Our research and development programs are focused on the development of immuno-oncology therapeutics based on our INTASYL therapeutic platform. Since we commenced operations, research and development expenses have been a significant portion of our total operating expenses and are expected to constitute the majority of our spending for the foreseeable future.

 

Research and development expenses for the three months ended March 31, 2024 decreased 46% as compared with the three months ended March 31, 2023. The decrease in research and development expenses was primarily driven by our cost rationalization measures in transitioning from a research company to a product development company resulting in a decrease of $305,000 of expense due to the wind-down of preclinical studies, $170,000 in salary-related costs, including stock-based compensation expense, and $108,000 in lab supplies associated with the reduction in headcount, in addition to a decrease in clinical consulting fees of $225,000 incurred in connection with our IND filing for PH-762 in the prior period and a decrease of $131,000 in manufacturing fees for PH-762.

 

 

 

 

 16 

 

 

General and Administrative Expenses

 

General and administrative expenses relate to compensation and benefits for general and administrative personnel, facility-related expenses, professional fees for legal and patent-related activities, audit, tax and consulting services, as well as other general corporate expenses.

 

General and administrative expenses for the three months ended March 31, 2024 decreased 28% as compared with the three months ended March 31, 2023. The decrease in general and administrative expenses was primarily due to decreases in consulting expenses of $102,000 and legal expenses of $211,000 as compared to the prior year period.

 

Liquidity and Capital Resources

 

Historically, our primary source of funding has been through the sale of our securities. In the future, we will be dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity or strategic opportunities, in order to maintain our operations. We have reported recurring losses from operations since inception and expect that we will continue to have negative cash flows from our operations for the foreseeable future. At March 31, 2024, we had cash of $6,475,000 as compared with $8,490,000 at December 31, 2023.

 

We have limited cash resources, have reported recurring losses from operations since inception, have negative operating cash flows and have not yet received product revenues. These factors raise substantial doubt regarding our ability to continue as a going concern, and our current cash resources may not provide sufficient capital to fund operations for at least the next 12 months from the date of the release of the condensed consolidated financial statements included elsewhere in this Quarterly Report. Our continuation as a going concern depends upon our ability to raise additional capital through equity offerings, debt offerings and/or strategic opportunities to fund our operations. There can be no assurance that we will be successful in accomplishing any of these plans in order to continue as a going concern. The condensed consolidated financial statements included elsewhere in this Quarterly Report do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

 

The following table summarizes our cash flows for the periods indicated, in thousands:

 

   Three Months Ended
March 31,		 
   2024   2023 
Net cash used in operating activities  $(2,011)  $(2,708)
Net cash used in financing activities   (4)   (38)
Net decrease in cash, cash equivalents and restricted cash  $(2,015)  $(2,746)

 

Net Cash Flow from Operating Activities

 

Net cash used in operating activities for the three months ended March 31, 2024 decreased 26% as compared to the three months ended March 31, 2023, primarily due to a decrease in net loss of $1,448,000, a decrease in non-cash related items of $89,000 primarily related to reduced stock-based compensation expense, and a decrease in the changes in operating assets and liabilities of $662,000 primarily as a result of liabilities owed to support our IND filing for PH-762 and manufacturing fees related to the fill/finish of PH-762 drug product in the prior year period.

 

Net Cash Flow from Investing Activities

 

There were no net cash flows from investing activities for the three months ended March 31, 2024 and 2023.

 

 

 

 17 

 

 

Net Cash Flow from Financing Activities

 

Net cash used in financing activities for the three months ended March 31, 2024 decreased 89% as compared to the three months ended March 31, 2023, primarily due to the amount of payments made for taxes on the net share settlements of RSUs.

 

Contractual Obligations

 

Details of our obligations under the Clinical Co-Development Agreement with our former collaboration partner AgonOx can be found in Note 2 of the condensed consolidated financial statements. Outside of the above, there have been no material changes to the contractual obligations as disclosed in our 2023 Form 10-K.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a smaller reporting company, we are not required to provide this information.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Principal Executive Officer (who is also acting as our Principal Financial Officer), evaluated the effectiveness of disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report to ensure that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.

 

Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Based on the evaluation of our disclosure controls and procedures as of the end of the period covered by this report, management, with the participation of our Principal Executive Officer (who is also acting as our Principal Financial Officer), concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.

 

Changes in Internal Control Over Financial Reporting

 

There have been no changes in our internal control over financial reporting that occurred during the quarter ending March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

 

 

 18 

 

 

PART II — OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, we may become a party to various legal proceedings and complaints arising in the ordinary course of business. We are not currently a party to any actual or threatened material legal proceedings of which we are aware.

 

ITEM 1A. RISK FACTORS

 

Other than set forth below, there have been no material changes in our risk factors set forth in Part I, “Item 1A. Risk Factors” in our 2023 Form 10-K. The risk factor set forth below and risk factors disclosed in Part I, “Item 1A. Risk Factors” in our 2023 Form 10-K could materially adversely affect our business, financial condition, or results of operations. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including these risks. Additional risks not currently known or currently material to us may also harm our business.

 

We may not be able to regain, or maintain, compliance with the continued listing requirements of The Nasdaq Capital Market.

 

On January 24, 2024, we received notice (the “Notification Letter”) from Nasdaq notifying us that we are not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of our common stock for the 30 consecutive business days prior to the date of the Notification Letter, we no longer meet the minimum bid price requirement.

 

The Notification Letter does not impact our listing on The Nasdaq Capital Market at this time. The Notification Letter states that we have 180 calendar days, or until July 22, 2024, to regain compliance. To regain compliance, the bid price of our common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to July 22, 2024. In the event that we do not regain compliance by July 22, 2024, we may be eligible for additional time to reach compliance with the minimum bid price requirement. However, if we fail to regain compliance with the minimum bid price listing requirement or fail to maintain compliance with all other applicable continued listing requirements and Nasdaq determines to delist our common stock, the delisting could adversely impact us by, among other things, reducing the liquidity and market price of our common stock; reducing the number of investors willing to hold or acquire our common stock; limiting our ability to issue additional securities in the future; and limiting our ability to fund our operations.

 

We are currently evaluating options to resolve such deficiency, including by effecting a reverse stock split of our common stock.

 

Additionally, Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2.5 million for continued listing. As of March 31, 2024, our stockholders’ equity was $5.6 million and there can be no assurance that we will be able to maintain or increase our stockholders’ equity in the future. If our stockholders equity falls below $2.5 million, as a result of operating losses or for other reasons, or if we are unable to demonstrate to Nasdaq’s satisfaction that we subsequently regained compliance with this requirement, Nasdaq will notify us of such non-compliance. If we receive such notice from Nasdaq, in accordance with the Nasdaq Listing Rules, we will have 45 calendar days from the date of the notification to submit a plan to regain compliance with Nasdaq Listing Rule 5550(b)(1). If our compliance plan is accepted, we may be granted up to 180 calendar days from the date of the initial notification to evidence compliance. If our compliance plan is not accepted or we are otherwise unable to evidence compliance within Nasdaq’s allotted timeframe, Nasdaq may take steps to delist our common stock.

 

Such a delisting would have an adverse effect on the market liquidity of our securities, decrease the market price of our securities, result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities, and adversely affect our ability to obtain financing for the continuation of our operations. We are actively monitoring our stockholders’ equity and will consider any and all options available to us to maintain compliance with Nasdaq Listing Rule 5550(b)(1).

 

 

 

 19 

 

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

No sales or issuances of unregistered securities occurred that have not previously been disclosed in a Current Report on Form 8-K.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

During the three months ended March 31, 2024, no director or officer of the Company adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

 

Termination of Clinical Co-Development Agreement with AgonOx

 

On May 8, 2024, we notified AgonOx, Inc. (“AgonOx”) of our election to terminate the Clinical Co-Development Agreement, dated February 26, 2021, by and between the Company and AgonOx (the “Clinical Co-Development Agreement”), effective immediately. We elected to terminate the Clinical Co-Development Agreement pursuant to Section 12.2.3.3 of the Clinical Co-Development Agreement due to enrollment delays in the Phase 1 clinical trial described below.

 

On February 26, 2021, we entered into the Clinical Co-Development Agreement with AgonOx to develop a T cell-based therapy using our lead product candidate, PH-762, and AgonOx’s “double positive” tumor infiltrating lymphocytes (“DP TIL”) technology. Per the terms of the Clinical Co-Development Agreement, we agreed to reimburse AgonOx up to $4,000,000 in expenses incurred to conduct a Phase 1 clinical trial of PH-762 treated DP TIL in patients with advanced melanoma and other advanced solid tumors. We were also eligible to receive certain future development milestones and low single-digit sales-based royalty payments from AgonOx’s licensing of its DP TIL technology.

 

Prior to the termination of the Clinical Co-Development Agreement with AgonOx, PH-762 treated DP TIL was being evaluated in a Phase 1 clinical trial in the United States with up to 18 patients with advanced melanoma and other advanced solid tumors by AgonOx. The primary trial objectives were to evaluate the safety and to study the potential for enhanced therapeutic benefit from the administration of PH-762 treated DP TIL. As of the effective date of the termination, AgonOx had treated three patients. The first two patients were treated with DP TIL only and the third patient was treated with a combination of DP TIL and PH-762.

 

Effective as of the date of termination, the Clinical Co-Development Agreement and our continuing obligations and those of AgonOx thereunder will be terminated in their entirety. We will no longer be required to provide financial support for the development costs incurred under the Clinical Co-Development Agreement or entitled to certain future development milestones and low single-digit sales-based royalty payments from AgonOx’s licensing of its DP TIL technology. We will pay to AgonOx all payment obligations that have accrued prior to the termination of the Clinical Co-Development Agreement. We intend to pay to AgonOx future fees to be incurred for patients that were treated in the Phase 1 clinical trial as of the date of termination. We estimate that such payments will amount to approximately $388,000, which primarily relate to the Company’s accrued obligations under the Clinical Co-Development Agreement as of March 31, 2024, as well as future fees to be incurred for patients that were being treated in the Phase 1 clinical trial and other miscellaneous costs as of the date of termination.

 

 

 

 20 

 

 

Pursuant to the terms of the Clinical Co-Development Agreement, we and AgonOx shall meet and discuss the orderly wind-down of the Phase 1 clinical trial. Each of us and AgonOx shall be responsible for its own costs and expenses incurred in connection with the wind-down of the Phase 1 clinical trial.

 

The foregoing summary of the Clinical Co-Development Agreement does not purport to be complete and is subject to, and qualified in its entirety by, reference to the full text of the Clinical Co-Development Agreement, a copy of which is filed as Exhibit 10.2 to our Form 10-K for the year ended December 31, 2023 and incorporated herein by reference.

 

 

ITEM 6. EXHIBITS

 

EXHIBIT INDEX

 

        Incorporated by Reference Herein

Exhibit
Number

   Description   Form   Date
             
31.1   Sarbanes-Oxley Act Section 302 Certification of Principal Executive Officer and Principal Financial Officer. *        
             
32.1   Sarbanes-Oxley Act Section 906 Certification of Principal Executive Officer and Principal Financial Officer. **        
             
101.INS   Inline XBRL Instance Document.*        
101.SCH   Inline XBRL Taxonomy Extension Schema Document.*        
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.*        
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.*        
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.*        
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.*        
104   The cover page for this report, formatted in Inline XBRL (included in Exhibit 101).*        

 

 _________________
* Filed herewith.
** Furnished herewith and not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section or incorporated by reference into any filing under the Securities Act or the Exchange Act.

 

 

 

 

 22 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Phio Pharmaceuticals Corp.
     
  By:   /s/ Robert J. Bitterman                            
      Robert J. Bitterman
     

President and Chief Executive Officer

(as Principal Executive and Financial Officer)

     
      Date: May 9, 2024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 23 

 

 EX-31.1 2 phio_ex3101.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

SECURITIES EXCHANGE ACT OF 1934 RULES 13a-14(a) AND 15d-14(a)

AS ADOPTED

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Robert J. Bitterman, certify that:

 

  1. I have reviewed this Quarterly Report on Form 10-Q of Phio Pharmaceuticals Corp.;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

 

Dated: May 9, 2024

   

/s/ Robert J. Bitterman

  
Robert J. Bitterman  
President and Chief Executive Officer  
(as Principal Executive and Financial Officer)

 

 EX-32.1 3 phio_ex3201.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

Exhibit 32.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Phio Pharmaceuticals Corp. (the “Company”) on Form 10-Q for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the Company’s financial condition and result of operations.

 

 

Dated: May 9, 2024

 

   
/s/ Robert J. Bitterman  
Robert J. Bitterman  
President and Chief Executive Officer  
(as Principal Executive and Financial Officer)

 

 EX-101.SCH 4 phio-20240331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Reconciliation of Cash and Restricted Cash link:presentationLink link:calculationLink link:definitionLink 995513 - Disclosure - Organization and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995514 - Disclosure - Collaboration Agreement link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 995516 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995517 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 995518 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 995519 - Disclosure - Net Loss per Common Share link:presentationLink link:calculationLink link:definitionLink 995520 - Disclosure - Organization and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995521 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 995522 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 995523 - Disclosure - Stockholders’ Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 995524 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Net Loss per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995526 - Disclosure - Collaboration Agreement (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995527 - Disclosure - Fair Value of Financial Instruments - (Details - Financial instruments at fair value) link:presentationLink link:calculationLink link:definitionLink 995528 - Disclosure - Leases (Details - Balance sheet lease items) link:presentationLink link:calculationLink link:definitionLink 995529 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995530 - Disclosure - Stockholders' Equity (Details - Warrants outstanding) link:presentationLink link:calculationLink link:definitionLink 995531 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995532 - Disclosure - Stock-based Compensation (Details - RSU activity) link:presentationLink link:calculationLink link:definitionLink 995533 - Disclosure - Stock-based Compensation (Details - Option activity) link:presentationLink link:calculationLink link:definitionLink 995534 - Disclosure - Stock-based Compensation (Details - Share-based compensation) link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Stock-based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995536 - Disclosure - Net Loss per Common Share (Details - Antidilutive shares) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 phio-20240331_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 phio-20240331_def.xml XBRL DEFINITION FILE EX-101.LAB 7 phio-20240331_lab.xml XBRL LABEL FILE Equity Components [Axis] Preferred Stock Series D [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Transaction Type [Axis] Clinical Co Development Agreement [Member] Counterparty Name [Axis] Agon Ox [Member] Asset Class [Axis] Cash and Cash Equivalents [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Property Subject to or Available for Operating Lease [Axis] Property Subject to Operating Lease [Member] Securities Financing Transaction [Axis] December 2023 Financing [Member] Award Type [Axis] Abeyance Shares [Member] Class of Stock [Axis] Warrant [Member] Restricted Stock Units (RSUs) [Member] Employees [Member] Non Employee Members [Member] Share-Based Payment Arrangement, Option [Member] Board Of Directors [Member] Statement of Income Location, Balance [Axis] Research and Development Expense [Member] General and Administrative Expense [Member] Antidilutive Securities [Axis] Stock Options [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Prepaid expenses and other current assets Total current assets Right of use asset Property and equipment, net Other assets Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable Accrued expenses Lease liability Total current liabilities Commitments and contingencies (Note 2) Stockholders’ equity: Preferred stock, $0.0001 par value, 100,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively Common stock, $0.0001 par value, 100,000,000 shares authorized; 4,591,700 and 3,747,329 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively Additional paid-in capital Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares, issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares, issued Common stock, shares outstanding Income Statement [Abstract] Operating expenses: Research and development General and administrative Total operating expenses Operating loss Total other income, net Net loss Net loss per common share: Net loss per common share, Basic Net loss per common share, Diluted Weighted average number of common shares outstanding: Weighted average number of common shares outstanding, Basic Weighted average number of common shares outstanding, Diluted Statement [Table] Statement [Line Items] Beginning balance, value Balance at beginning, shares Issuance of common stock upon exercise of warrants Issuance of common stock upon exercise of warrants, shares Cash-in-lieu of fractional shares for reverse stock split Cash-in-lieu of fractional shares for reverse stock split, shares Redemption of preferred stock Redemption of preferred stock, shares Issuance of common stock upon vesting of restricted stock units Issuance of common stock upon vesting of restricted stock units, shares Shares withheld for payroll taxes Shares withheld for payroll taxes, shares Stock-based compensation expense Net loss Ending balance, value Balance at ending, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Amortization of right of use asset Loss on disposal of property and equipment Stock-based compensation Changes in operating assets and liabilities: Prepaid expenses and other assets Accounts payable Accrued expenses Lease liability Net cash used in operating activities Cash flows from financing activities: Cash in lieu of fractional shares for reverse stock split Redemption of Series D preferred stock Payment of taxes on net share settlements of restricted stock units Net cash used in financing activities Net decrease in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at the beginning of period Cash, cash equivalents and restricted cash at the end of period Cash and cash equivalents Restricted cash Cash, cash equivalents and restricted cash Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Trading Arrangements, by Individual [Table] Trading Arrangement [Axis] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Accounting Policies [Abstract] Organization and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements [Abstract] Collaboration Agreement Fair Value Disclosures [Abstract] Fair Value of Financial Instruments Leases [Abstract] Leases Equity [Abstract] Stockholders’ Equity Share-Based Payment Arrangement [Abstract] Stock-based Compensation Earnings Per Share [Abstract] Net Loss per Common Share Nature of Operations Basis of Presentation Principles of Consolidation Segments Use of Estimates Liquidity Summary of Significant Accounting Policies Recent Accounting Pronouncements Schedule of financial instruments at fair value Schedule of lease amounts recorded in balance sheet Schedule of outstanding warrants Summary of RSU activity Summary of stock option activity Schedule of stock-based compensation expense Schedule of anti dilutive stock Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Expense from contractual obligations Contractual obligation Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Total Assets Liabilities Total lease liability Lease Term and Discount Rate Weighted average remaining lease term Weighted average discount rate Operating lease footage Lease expiration date Total base rent Operating lease costs Operating lease payments Stock, Class of Stock [Table] Class of Stock [Line Items] Warrants outstanding, beginning Warrants outstanding, weighted average exercise price Warrants issued, shares Warrants issued, weighted average exercise price Warrants exercised, shares Warrants exercised, weighted average exercise price Warrants expired, shares Warrants expired, weighted average exercise price Warrants outstanding Warrants outstanding, weighted average exercise price Security Financing Transaction [Table] [custom:AmendedWarrants] Common Stock, Capital Shares Reserved for Future Issuance Warrants exercised shares Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] RSU's unvested units, beginning balance RSU beginning balance, price per share RSU's granted RSU's granted, price per share RSU's vested RSU's vested, price per share RSU's forfeited RSU's forfeited, price per share RSU's unvested units, ending balance RSU ending balance, price per share Number of shares outstanding, Beginning Weighted average exercise price per share, Beginning Number of shares outstanding, Granted Weighted average exercise price per share, Granted Number of shares outstanding, Exercised Weighted average exercise price per share, Exercised Number of shares outstanding, Forfeited Weighted average exercise price per share, Forfeited Number of shares outstanding, Expired Weighted average exercise price per share, Expired Number of shares outstanding, Ending Weighted average exercise price per share, Ending Aggregate intrinsic value, Outstanding Number of shares outstanding, Exercisable Weighted average exercise price per share, Exercisable Aggregate intrinsic value, Exercisable Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total stock-based compensation Vesting period Share-based compensation expense Fair value of awards vested Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive shares Assets, Current Assets [Default Label] Liabilities, Current Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Shares, Outstanding Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Gain (Loss) on Disposition of Property Plant Equipment Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Operating Lease Liability Net Cash Provided by (Used in) Operating Activities CashInLieuOfFractionalSharesForReverseStockSplit Payments for Repurchase of Redeemable Preferred Stock Payment, Tax Withholding, Share-Based Payment Arrangement Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Class of Warrant or Right, Outstanding ClassOfWarrantOrRightWeightedAverageExercisePrice WarrantsExercisedShare WarrantsExpiredShares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period EX-101.PRE 8 phio-20240331_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover - shares
 3 Months Ended
Mar. 31, 2024
May 03, 2024
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2024  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2024  
Current Fiscal Year End Date --12-31  
Entity File Number 001-36304  
Entity Registrant Name Phio Pharmaceuticals Corp.  
Entity Central Index Key 0001533040  
Entity Tax Identification Number 45-3215903  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 11 Apex Drive  
Entity Address, Address Line Two Suite 300A, PMB 2006  
Entity Address, City or Town Marlborough  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 01752  
City Area Code 508  
Local Phone Number 767-3861  
Title of 12(b) Security Common Stock, par value, $0.0001 per share  
Trading Symbol PHIO  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   4,591,700
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 6,475 $ 8,490
Prepaid expenses and other current assets 373 832
Total current assets 6,848 9,322
Right of use asset 0 33
Property and equipment, net 2 6
Other assets 3 3
Total assets 6,853 9,364
Current liabilities:    
Accounts payable 320 657
Accrued expenses 929 942
Lease liability 0 35
Total current liabilities 1,249 1,634
Commitments and contingencies (Note 2)
Stockholders’ equity:    
Preferred stock, $0.0001 par value, 100,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 0 0
Common stock, $0.0001 par value, 100,000,000 shares authorized; 4,591,700 and 3,747,329 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 0 0
Additional paid-in capital 146,964 146,936
Accumulated deficit (141,360) (139,206)
Total stockholders’ equity 5,604 7,730
Total liabilities and stockholders’ equity $ 6,853 $ 9,364
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 100,000,000 100,000,000
Preferred stock, shares, issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares, issued 4,591,700 3,747,329
Common stock, shares outstanding 4,591,700 3,747,329
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Research and development $ 1,148 $ 2,134
General and administrative 1,061 1,468
Total operating expenses 2,209 3,602
Operating loss (2,209) (3,602)
Total other income, net 55 0
Net loss $ (2,154) $ (3,602)
Net loss per common share:    
Net loss per common share, Basic $ (0.47) $ (3.15)
Net loss per common share, Diluted $ (0.47) $ (3.15)
Weighted average number of common shares outstanding:    
Weighted average number of common shares outstanding, Basic 4,580,072 1,142,213
Weighted average number of common shares outstanding, Diluted 4,580,072 1,142,213
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS' EQUITY (Unaudited) - USD ($)
$ in Thousands
Preferred Stock Series D [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2022 $ 2 $ 0 $ 139,218 $ (128,380) $ 10,838
Balance at beginning, shares at Dec. 31, 2022 1 1,139,024      
Cash-in-lieu of fractional shares for reverse stock split (11) (11)
Cash-in-lieu of fractional shares for reverse stock split, shares   (1,706)      
Redemption of preferred stock $ (2)
Redemption of preferred stock, shares (1)        
Issuance of common stock upon vesting of restricted stock units
Issuance of common stock upon vesting of restricted stock units, shares   18,080      
Shares withheld for payroll taxes (25) (25)
Shares withheld for payroll taxes, shares   (4,816)      
Stock-based compensation expense 111 111
Net loss (3,602) (3,602)
Ending balance, value at Mar. 31, 2023 $ 0 $ 0 139,293 (131,982) 7,311
Balance at ending, shares at Mar. 31, 2023 0 1,150,582      
Beginning balance, value at Dec. 31, 2023 $ 0 $ 0 146,936 (139,206) 7,730
Balance at beginning, shares at Dec. 31, 2023 0 3,747,329      
Issuance of common stock upon exercise of warrants
Issuance of common stock upon exercise of warrants, shares   826,370      
Issuance of common stock upon vesting of restricted stock units
Issuance of common stock upon vesting of restricted stock units, shares   24,198      
Shares withheld for payroll taxes (4) (4)
Shares withheld for payroll taxes, shares   (6,197)      
Stock-based compensation expense 32 32
Net loss (2,154) (2,154)
Ending balance, value at Mar. 31, 2024 $ 0 $ 0 $ 146,964 $ (141,360) $ 5,604
Balance at ending, shares at Mar. 31, 2024 0 4,591,700      
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net loss $ (2,154) $ (3,602)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1 16
Amortization of right of use asset 33 31
Loss on disposal of property and equipment 3 0
Stock-based compensation 32 111
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 459 314
Accounts payable (337) 123
Accrued expenses (13) 331
Lease liability (35) (32)
Net cash used in operating activities (2,011) (2,708)
Cash flows from financing activities:    
Cash in lieu of fractional shares for reverse stock split 0 (11)
Redemption of Series D preferred stock 0 (2)
Payment of taxes on net share settlements of restricted stock units (4) (25)
Net cash used in financing activities (4) (38)
Net decrease in cash, cash equivalents and restricted cash (2,015) (2,746)
Cash, cash equivalents and restricted cash at the beginning of period 8,490 11,831
Cash, cash equivalents and restricted cash at the end of period $ 6,475 $ 9,085
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Reconciliation of Cash and Restricted Cash - USD ($)
$ in Thousands
Mar. 31, 2024
Mar. 31, 2023
Statement of Financial Position [Abstract]    
Cash and cash equivalents $ 6,475 $ 9,035
Restricted cash 0 50
Cash, cash equivalents and restricted cash $ 6,475 $ 9,085
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure [Table]    
Net Income (Loss) $ (2,154) $ (3,602)
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Organization and Significant Accounting Policies
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Organization and Significant Accounting Policies

1. Organization and Significant Accounting Policies

 

Nature of Operations

 

Phio Pharmaceuticals Corp. (“Phio” or the “Company”) is a clinical stage biotechnology company whose proprietary INTASYL™ small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.

 

Phio was incorporated in the state of Delaware in 2011 as RXi Pharmaceuticals Corporation. On November 19, 2018, the Company changed its name to Phio Pharmaceuticals Corp., to reflect its transition from a platform company to one that is fully committed to developing groundbreaking immuno-oncology therapeutics.

 

Basis of Presentation

 

The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Certain information and footnote disclosures that are included in the Company’s annual consolidated financial statements, but that are not required for interim reporting purposes, have been condensed or omitted. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included.

 

These statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024 (the “2023 Form 10-K”). Interim results are not necessarily indicative of results for a full year.

 

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, MirImmune, LLC. All material intercompany accounts have been eliminated in consolidation.

 

Segments

 

The Company operates as one operating segment and all assets are located in the United States.

 

Use of Estimates

 

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas subject to significant estimates and judgement include, among others, those related to the fair value of equity awards, accruals for research and development expenses, useful lives of property and equipment, and the valuation allowance on the Company’s deferred tax assets. On an ongoing basis the Company evaluates its estimates and bases its estimates on historical experience and other relevant assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from these estimates.

 

Liquidity

 

The Company has reported recurring losses from operations since its inception and expects to continue to have negative cash flows from operations for the foreseeable future. Historically, the Company’s primary source of funding has been from sales of its securities. The Company’s ability to continue to fund its operations is dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, or strategic opportunities, in order to maintain its operations. This is dependent on a number of factors, including the market demand or liquidity of the Company’s common stock. There is no guarantee that debt, additional equity or other funding will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, the Company would be forced to scale back or terminate its operations or seek to merge with or to be acquired by another company.

 

The Company has limited cash resources, has reported recurring losses from operations since inception, has negative operating cash flows and has not yet received product revenues. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern, and the Company’s current cash resources may not provide sufficient capital to fund operations for at least the next 12 months from the date of the release of these condensed consolidated financial statements. The continuation of the Company as a going concern depends upon the Company’s ability to raise additional capital through an equity offering, debt offering and/or strategic opportunity to fund its operations. There can be no assurance that the Company will be successful in accomplishing these plans in order to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Summary of Significant Accounting Policies

 

Cash and Cash Equivalents

 

Cash and cash equivalents include unrestricted cash accounts, money market investments and highly liquid investment instruments with original maturity of three months or less at the date of purchase.

 

Other than as set forth above, there have been no material changes to the significant accounting policies disclosed in the Company’s 2023 Form 10-K.

 

Recent Accounting Pronouncements

 

In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting (Topic 280) – Improvements to Reporting Segment Disclosures” (“ASU 2023-07”), which requires disclosure of incremental segment information on an annual and interim basis. In addition, ASU 2023-07 clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and contains other disclosure requirements. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The enhanced disclosures are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of ASU 2023-07 on its consolidated financial statements and disclosures, but does not expect that it will have a material impact on its consolidated financial statements.

 

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740) – Improvements to Income Tax Disclosures” (“ASU 2023-09”), which requires disclosure of specific categories in the rate reconciliation table along with additional information for reconciling items that meet a quantitative threshold, disclosure of disaggregated income taxes paid and modifies other income tax-related disclosures. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-09, but does not expect that it will have a material impact on its consolidated financial statements.

 
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaboration Agreement
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaboration Agreement

2. Collaboration Agreement

 

AgonOx, Inc. (“AgonOx”)

 

In February 2021, the Company entered into a clinical co-development collaboration agreement (the “Clinical Co-Development Agreement”) with AgonOx, a private company developing a pipeline of novel immunotherapy drugs targeting key regulators of the immune response to cancer. Under the Clinical Co-Development Agreement, Phio and AgonOx are working to develop a T cell-based therapy using the Company’s lead product candidate, PH-762, and AgonOx’s “double positive” tumor infiltrating lymphocytes (“DP TIL”) technology. Per the terms of the Clinical Co-Development Agreement, the Company agreed to reimburse AgonOx up to $4,000,000 in expenses incurred to conduct a Phase 1 clinical trial of PH-762 treated DP TIL in patients with advanced melanoma and other advanced solid tumors.

 

The Company recognizes its share of costs arising from research and development activities performed by AgonOx in the Company’s condensed consolidated financial statements in the period AgonOx incurs such expense. Phio will be entitled to certain future development milestones and low single-digit sales-based royalty payments from AgonOx’s licensing of its DP TIL technology.

 

The Company recognized approximately $50,000 and $119,000 of expense in connection with these efforts during the three months ended March 31, 2024 and 2023, respectively.

 

On May 8, 2024, the Company terminated its Clinical Co-Development Agreement with AgonOx, effective immediately. Effective as of the date of the termination, the Clinical Co-Development Agreement and the continuing obligations of the Company and AgonOx thereunder will be terminated in their entirety. The Company will no longer be required to provide financial support for the development costs incurred under the Clinical Co-Development Agreement or be entitled to certain future development milestones and low single-digit sales-based royalty payments from AgonOx’s licensing of its DP TIL technology.

 

The Company will pay to AgonOx all Company payment obligations that have accrued prior to the termination of the Clinical Co-Development Agreement. The Company intends to pay to AgonOx future fees to be incurred for patients that were treated in the Phase 1 clinical trial as of the date of termination. The Company estimates that such payments to be made to AgonOx will amount to approximately $388,000, which primarily relate to the Company’s accrued obligations under the Clinical Co-Development Agreement as of March 31, 2024, as well as future fees to be incurred for patients that were treated in the Phase 1 clinical trial and other miscellaneous costs as of the date of termination. Pursuant to the terms of the Clinical Co-Development Agreement, the Company and AgonOx shall meet and discuss the orderly wind-down of the Phase 1 clinical trial. Each of the Company and AgonOx shall be responsible for its own costs and expenses incurred in connection with the wind-down of the Phase 1 clinical trial. See Item 5. Other Information included elsewhere in this Quarterly Report for further information.

 
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value of Financial Instruments
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments

3. Fair Value of Financial Instruments

 

The Company follows the provisions of the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 820, “Fair Value Measurement,” for the Company’s financial assets and liabilities that are re-measured and reported at fair value each reporting period and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:

 

Level 1 – quoted prices in active markets for identical assets or liabilities.

 

Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

 

Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

 

As of March 31, 2024, the Company categorized its cash equivalents as Level 1 hierarchy as the carrying amounts approximate their fair value due to their short-term nature and market rates of interest. As of December 31, 2023, the Company did not identify any financial instruments required to be presented at fair value.

                    
Description  March 31, 2024  

Quoted Prices

In Active Markets
(Level 1)

    Other Significant
Observable Inputs
(Level 2)		   Unobservable
Inputs
(Level 3)		 
Assets:                    
Cash equivalents  $6,379   $6,379   $–   $– 
Total  $6,379   $6,379   $–   $– 

 

The carrying amounts of cash, accounts payable and accrued expenses of the Company approximate their fair values due to their short-term nature.

 
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Leases

4. Leases

 

The Company’s lease for its corporate headquarters and primary research facility in Marlborough, Massachusetts was for a total of 7,581 square feet of office and laboratory space and expired on March 31, 2024. The lease agreement did not contain information to determine the borrowing rate implicit in the lease. As such, the Company calculated its incremental borrowing rate based on what the Company would have to pay to borrow on a collateralized basis over the lease term for an amount equal to the remaining lease payments, taking into consideration such assumptions as, but not limited to, the U.S. treasury yield rate and borrowing rates from a creditworthy financial institution using the above lease factors. The Company has continued operations as a primarily remote business with the expiration of the lease, but has contracted a private mailbox with an address of 11 Apex Drive, Suite 300A, PMB 2006, Marlborough, MA 01752 to use as its principal mailing address for SEC and other purposes.

 

The Company entered into a lease for a laboratory facility located at 17 Briden Street, Worcester, Massachusetts, which commenced on March 1, 2024. The lease covers 321 square feet of rentable space and expires on September 1, 2024. The total base rent for the premises over the term is expected to be $15,000 and the Company has the option to renew for additional 6-month periods. The Company made an accounting policy election under the FASB ASC Topic 824, “Leases” not to recognize leases with a term less than one year on the balance sheet and that do not contain a purchase option. Under the short-term lease election, the Company will recognize the lease payments for the laboratory facility on a straight-line basis over the lease term.

 

The lease for the Company’s corporate headquarters represented all of our significant lease obligations.

 

The amounts reported in the condensed consolidated balance sheets for the Company’s corporate headquarters classified as an operating lease in which the Company is the lessee and other supplemental balance sheet information is set forth as follows, in thousands, except the lease term (number of years) and discount rate:

        
   March 31, 2024   December 31, 2023 
Assets          
Right of use asset  $–   $33 
Liabilities          
Lease liability  $–   $35 
Lease Term and Discount Rate          
Weighted average remaining lease term   –    0.25 
Weighted average discount rate   4.70%    4.70% 

 

Operating lease costs included in operating expense were $33,000 for the three months ended March 31, 2024 and 2023, respectively.

  

Cash paid for the amounts included in the measurement of the operating lease liability on the Company’s condensed consolidated balance sheets and included within changes in the lease liability in the operating activities of the Company’s condensed consolidated statements of cash flows was $35,000 and $34,000 for the three months ended March 31, 2024 and 2023, respectively.

 
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders’ Equity
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Stockholders’ Equity

5. Stockholders’ Equity

 

Warrants

 

The Company first assesses warrants that are issued by the Company under the FASB ASC Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”) to determine whether the warrants are within the scope of ASC 480. If there are no instances outside of the Company’s control that could require cash settlement, the Company then applies and follows the applicable accounting guidance in the FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). Financial instruments are accounted for as either derivative liabilities or equity instruments depending on the specific terms of the agreement. Based on the assessment of the warrants issued by the Company under the guidance in ASC 480 and ASC 815, the warrants issued by the Company have been classified within stockholder’s equity.

 

In December 2023, the Company entered into an inducement letter agreement (the “Inducement Letter Agreement”) with certain holders of the Company’s existing warrants to purchase up to an aggregate of 2,130,252 shares of the Company’s common stock (the “December 2023 Financing”). Pursuant to the terms of the Inducement Letter Agreement, in the event that the exercise of the existing warrants in the December 2023 Financing would have otherwise caused a holder to exceed the beneficial ownership limitations set forth in the existing warrant, the Company issued the number of shares that would not cause a holder to exceed such beneficial ownership limitation and agreed to hold such balance of shares of common stock in abeyance. Accordingly, an aggregate of 826,370 shares of common stock were held in abeyance (the “Abeyance Shares”) with such Abeyance Shares evidenced through the holder’s existing warrants and which were deemed to be prepaid. The Abeyance Shares were held until notice was received by the holder that the balance of the shares of common stock could be issued in compliance with such beneficial ownership limitations and were exercised pursuant to a notice of exercise from the holder. Until such time, the Abeyance Shares were evidenced through the holder’s existing warrants and have been included in the Company’s table of outstanding warrants below.

 

During the three months ended March 31, 2024, all of the Abeyance Shares were released and issued. There were no warrant exercises during the three months ended March 31, 2023.

 

The following table summarizes the Company’s outstanding warrants, all of which are classified as equity instruments, at March 31, 2024:

          
    Number
of Shares		   Weighted-
Average
Exercise Price
Per Share		 
Outstanding at December 31, 2023   6,331,288   $3.68 
Issued   –    – 
Exercised   (826,370)   1.33 
Expired   –    – 
Outstanding at March 31, 2024   5,504,918   $4.03 

 
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-based Compensation
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation

6. Stock-based Compensation

 

Restricted Stock Units

 

Restricted stock units (“RSUs”) are issued under the Company’s 2020 Long-Term Incentive Plan (the “2020 Plan”) or as inducement grants issued outside of the 2020 Plan to new employees. RSUs are generally subject to graded vesting and the satisfaction of certain service requirements. RSUs granted by the Company to employees generally vest annually over 3 years after the grant date and over 1 year after the grant date for non-employee members of the Board of Directors. Upon vesting, each outstanding RSU will be settled for one share of the Company’s common stock. Employee RSU recipients may elect to net share settle upon vesting, in which case the Company pays the employee’s income taxes due upon vesting and withholds a number of shares of equal value. The Company does not expect to repurchase shares to satisfy RSU vests. The fair value of the RSUs awarded are based upon the Company’s closing stock price at the grant date and are expensed over the requisite service period.

 

The following table summarizes the activity of the Company’s RSUs for the three months ended March 31, 2024:

          
   Number
of Shares		   Weighted-
Average
Grant Date Fair Value
Per Share		 
Unvested units at December 31, 2023   49,683   $8.32 
Granted   –    – 
Vested   (24,198)   8.80 
Forfeited   (6,903)   10.96 
Unvested units at March 31, 2024   18,582   $6.70 

 

There were no RSUs granted during the three months ended March 31, 2024. The weighted-average fair value of RSUs granted during the three months ended March 31, 2023 was $5.24.

  

Stock-based compensation expense related to RSUs was $26,000 and $111,000 for the three months ended March 31, 2024 and 2023, respectively.

 

The aggregate fair value of awards that vested during the three months ended March 31, 2024 and 2023 was $17,000 and $95,000, respectively, which represents the market value of the Company’s common stock on the date that the RSUs vested.

 

Stock Options

 

Stock options are available for issuance under the 2020 Plan or as inducement grants issued outside of the 2020 Plan to new employees. Stock options are generally subject to graded vesting and the satisfaction of service requirements. Stock options granted by the Company to employees generally vest annually over 4 years after the grant date and generally vest over 1 year after the grant date for members of the Board of Directors and expire within ten years of grant. Upon the exercise of a stock option, the Company issues new shares and delivers them to the recipient. The Company does not expect to repurchase shares to satisfy stock option exercises.

 

The Company uses the Black-Scholes option-pricing model to determine the fair value of all its option grants. The risk-free interest rate used for each grant was based upon the yield on zero-coupon U.S. Treasury securities with a term similar to the expected life of the related option. The Company’s expected stock price volatility assumption is based upon the Company’s own implied volatility. As the Company has limited stock option exercise information, the expected life assumption used for option grants is based upon the simplified method provided for under the FASB ASC Topic 718, “Compensation — Stock Compensation”. The dividend yield assumption is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends.

 

The Company did not grant any stock options during the three months ended March 31, 2024 and 2023.

 

The following table summarizes the activity of the Company’s stock options for the three months ended March 31, 2024:

               
   Number
of Shares		   Weighted-
Average
Exercise
Price
Per Share		   Aggregate
Intrinsic
Value		 
Balance at December 31, 2023   10,084   $134.86      
Granted   –    –      
Exercised   –    –      
Forfeited   –    –      
Expired   (23)   13,541.48      
Balance at March 31, 2024   10,061   $104.21   $– 
Exercisable at March 31, 2024   10,061   $104.21   $– 

 

Stock-based compensation expense related to stock options for the three months ended March 31, 2024 was $6,000. The Company did not have any stock-based compensation expense related to stock options for the three months ended March 31, 2023.

 

Compensation Expense Related to Equity Awards

 

The following table sets forth total stock-based compensation expense for the three months ended March 31, 2024 and 2023, in thousands:

          
   March 31, 
   2024   2023 
Research and development  $(11)  $63 
General and administrative   43    48 
Total stock-based compensation  $32   $111 

 
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Loss per Common Share
 3 Months Ended
Mar. 31, 2024
Net loss per common share:  
Net Loss per Common Share

7. Net Loss per Common Share

 

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing the Company’s net loss by the weighted average number of common shares outstanding and the impact of the dilutive effect of potential common stock equivalents, except when the inclusion of such potential common stock equivalents would be anti-dilutive. Dilutive potential common stock equivalents primarily consist of stock options, RSUs and warrants. Therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented because the impact of these items is generally anti-dilutive during periods of net loss.

 

The following table sets forth the potential common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:

          
   March 31, 
   2024   2023 
Stock options   10,061    177 
Unvested RSUs   18,582    72,755 
Warrants   5,504,918    545,401 
Total   5,533,561    618,333 

 
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Organization and Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Nature of Operations

Nature of Operations

 

Phio Pharmaceuticals Corp. (“Phio” or the “Company”) is a clinical stage biotechnology company whose proprietary INTASYL™ small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.

 

Phio was incorporated in the state of Delaware in 2011 as RXi Pharmaceuticals Corporation. On November 19, 2018, the Company changed its name to Phio Pharmaceuticals Corp., to reflect its transition from a platform company to one that is fully committed to developing groundbreaking immuno-oncology therapeutics.

 
Basis of Presentation

Basis of Presentation

 

The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Certain information and footnote disclosures that are included in the Company’s annual consolidated financial statements, but that are not required for interim reporting purposes, have been condensed or omitted. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included.

 

These statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024 (the “2023 Form 10-K”). Interim results are not necessarily indicative of results for a full year.

 
Principles of Consolidation

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, MirImmune, LLC. All material intercompany accounts have been eliminated in consolidation.

 
Segments

Segments

 

The Company operates as one operating segment and all assets are located in the United States.

 
Use of Estimates

Use of Estimates

 

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas subject to significant estimates and judgement include, among others, those related to the fair value of equity awards, accruals for research and development expenses, useful lives of property and equipment, and the valuation allowance on the Company’s deferred tax assets. On an ongoing basis the Company evaluates its estimates and bases its estimates on historical experience and other relevant assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from these estimates.

 
Liquidity

Liquidity

 

The Company has reported recurring losses from operations since its inception and expects to continue to have negative cash flows from operations for the foreseeable future. Historically, the Company’s primary source of funding has been from sales of its securities. The Company’s ability to continue to fund its operations is dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, or strategic opportunities, in order to maintain its operations. This is dependent on a number of factors, including the market demand or liquidity of the Company’s common stock. There is no guarantee that debt, additional equity or other funding will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, the Company would be forced to scale back or terminate its operations or seek to merge with or to be acquired by another company.

 

The Company has limited cash resources, has reported recurring losses from operations since inception, has negative operating cash flows and has not yet received product revenues. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern, and the Company’s current cash resources may not provide sufficient capital to fund operations for at least the next 12 months from the date of the release of these condensed consolidated financial statements. The continuation of the Company as a going concern depends upon the Company’s ability to raise additional capital through an equity offering, debt offering and/or strategic opportunity to fund its operations. There can be no assurance that the Company will be successful in accomplishing these plans in order to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 
Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

 

Cash and Cash Equivalents

 

Cash and cash equivalents include unrestricted cash accounts, money market investments and highly liquid investment instruments with original maturity of three months or less at the date of purchase.

 

Other than as set forth above, there have been no material changes to the significant accounting policies disclosed in the Company’s 2023 Form 10-K.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting (Topic 280) – Improvements to Reporting Segment Disclosures” (“ASU 2023-07”), which requires disclosure of incremental segment information on an annual and interim basis. In addition, ASU 2023-07 clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and contains other disclosure requirements. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The enhanced disclosures are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of ASU 2023-07 on its consolidated financial statements and disclosures, but does not expect that it will have a material impact on its consolidated financial statements.

 

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740) – Improvements to Income Tax Disclosures” (“ASU 2023-09”), which requires disclosure of specific categories in the rate reconciliation table along with additional information for reconciling items that meet a quantitative threshold, disclosure of disaggregated income taxes paid and modifies other income tax-related disclosures. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-09, but does not expect that it will have a material impact on its consolidated financial statements.

 
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value of Financial Instruments (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of financial instruments at fair value
                    
Description  March 31, 2024  

Quoted Prices

In Active Markets
(Level 1)

    Other Significant
Observable Inputs
(Level 2)		   Unobservable
Inputs
(Level 3)		 
Assets:                    
Cash equivalents  $6,379   $6,379   $–   $– 
Total  $6,379   $6,379   $–   $– 
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases (Tables)
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Schedule of lease amounts recorded in balance sheet
        
   March 31, 2024   December 31, 2023 
Assets          
Right of use asset  $–   $33 
Liabilities          
Lease liability  $–   $35 
Lease Term and Discount Rate          
Weighted average remaining lease term   –    0.25 
Weighted average discount rate   4.70%    4.70% 
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders’ Equity (Tables)
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Schedule of outstanding warrants
          
    Number
of Shares		   Weighted-
Average
Exercise Price
Per Share		 
Outstanding at December 31, 2023   6,331,288   $3.68 
Issued   –    – 
Exercised   (826,370)   1.33 
Expired   –    – 
Outstanding at March 31, 2024   5,504,918   $4.03 
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-based Compensation (Tables)
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Summary of RSU activity
          
   Number
of Shares		   Weighted-
Average
Grant Date Fair Value
Per Share		 
Unvested units at December 31, 2023   49,683   $8.32 
Granted   –    – 
Vested   (24,198)   8.80 
Forfeited   (6,903)   10.96 
Unvested units at March 31, 2024   18,582   $6.70 
Summary of stock option activity
               
   Number
of Shares		   Weighted-
Average
Exercise
Price
Per Share		   Aggregate
Intrinsic
Value		 
Balance at December 31, 2023   10,084   $134.86      
Granted   –    –      
Exercised   –    –      
Forfeited   –    –      
Expired   (23)   13,541.48      
Balance at March 31, 2024   10,061   $104.21   $– 
Exercisable at March 31, 2024   10,061   $104.21   $– 
Schedule of stock-based compensation expense
          
   March 31, 
   2024   2023 
Research and development  $(11)  $63 
General and administrative   43    48 
Total stock-based compensation  $32   $111 

 
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Loss per Common Share (Tables)
 3 Months Ended
Mar. 31, 2024
Net loss per common share:  
Schedule of anti dilutive stock
          
   March 31, 
   2024   2023 
Stock options   10,061    177 
Unvested RSUs   18,582    72,755 
Warrants   5,504,918    545,401 
Total   5,533,561    618,333 
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaboration Agreement (Details Narrative) - Clinical Co Development Agreement [Member] - Agon Ox [Member] - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expense from contractual obligations $ 50,000 $ 119,000  
Contractual obligation     $ 388,000
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value of Financial Instruments - (Details - Financial instruments at fair value)
$ in Thousands
Mar. 31, 2024
USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Total $ 6,379
Fair Value, Inputs, Level 1 [Member]  
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Total 6,379
Fair Value, Inputs, Level 2 [Member]  
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Total 0
Fair Value, Inputs, Level 3 [Member]  
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Total 0
Cash and Cash Equivalents [Member]  
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Total 6,379
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member]  
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Total 6,379
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member]  
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Total 0
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 3 [Member]  
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Total $ 0
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases (Details - Balance sheet lease items) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Assets    
Right of use asset $ 0 $ 33
Liabilities    
Total lease liability $ 0 $ 35
Lease Term and Discount Rate    
Weighted average remaining lease term   3 months
Weighted average discount rate 4.70% 4.70%
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Leases (Details Narrative)
 3 Months Ended
Mar. 01, 2024
USD ($)
ft²
Mar. 31, 2024
USD ($)
ft²
Mar. 31, 2023
USD ($)
Operating lease costs   $ 33,000 $ 33,000
Operating lease payments   $ 35,000 $ 34,000
Property Subject to Operating Lease [Member]      
Operating lease footage | ft² 321 7,581  
Lease expiration date Sep. 01, 2024 Mar. 31, 2024  
Total base rent $ 15,000    
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders' Equity (Details - Warrants outstanding) - Warrant [Member]
 3 Months Ended
Mar. 31, 2024
$ / shares
shares
Class of Stock [Line Items]  
Warrants outstanding, beginning | shares 6,331,288
Warrants outstanding, weighted average exercise price | $ / shares $ 3.68
Warrants issued, shares | shares 0
Warrants issued, weighted average exercise price | $ / shares $ 0
Warrants exercised, shares | shares (826,370)
Warrants exercised, weighted average exercise price | $ / shares $ 1.33
Warrants expired, shares | shares 0
Warrants expired, weighted average exercise price | $ / shares $ 0
Warrants outstanding | shares 5,504,918
Warrants outstanding, weighted average exercise price | $ / shares $ 4.03
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders’ Equity (Details Narrative) - shares
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Class of Stock [Line Items]    
Warrants exercised shares 0  
Abeyance Shares [Member]    
Class of Stock [Line Items]    
Common Stock, Capital Shares Reserved for Future Issuance   826,370
December 2023 Financing [Member]    
Class of Stock [Line Items]    
[custom:AmendedWarrants]   2,130,252
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-based Compensation (Details - RSU activity) - Restricted Stock Units (RSUs) [Member] - $ / shares
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
RSU's unvested units, beginning balance 49,683  
RSU beginning balance, price per share $ 8.32  
RSU's granted 0  
RSU's granted, price per share $ 0 $ 5.24
RSU's vested (24,198)  
RSU's vested, price per share $ 8.80  
RSU's forfeited (6,903)  
RSU's forfeited, price per share $ 10.96  
RSU's unvested units, ending balance 18,582  
RSU ending balance, price per share $ 6.70  
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-based Compensation (Details - Option activity) - Share-Based Payment Arrangement, Option [Member]
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2024
USD ($)
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of shares outstanding, Beginning | shares 10,084
Weighted average exercise price per share, Beginning | $ / shares $ 134.86
Number of shares outstanding, Granted | shares 0
Weighted average exercise price per share, Granted | $ / shares $ 0
Number of shares outstanding, Exercised | shares 0
Weighted average exercise price per share, Exercised | $ / shares $ 0
Number of shares outstanding, Forfeited | shares 0
Weighted average exercise price per share, Forfeited | $ / shares $ 0
Number of shares outstanding, Expired | shares (23)
Weighted average exercise price per share, Expired | $ / shares $ 13,541.48
Number of shares outstanding, Ending | shares 10,061
Weighted average exercise price per share, Ending | $ / shares $ 104.21
Aggregate intrinsic value, Outstanding | $ $ 0
Number of shares outstanding, Exercisable | shares 10,061
Weighted average exercise price per share, Exercisable | $ / shares $ 104.21
Aggregate intrinsic value, Exercisable | $ $ 0
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-based Compensation (Details - Share-based compensation) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation $ 32 $ 111
Research and Development Expense [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation (11) 63
General and Administrative Expense [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation $ 43 $ 48
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-based Compensation (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Share-based compensation expense $ 32,000 $ 111,000
Restricted Stock Units (RSUs) [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
RSU's granted, price per share $ 0 $ 5.24
Share-based compensation expense $ 26,000 $ 111,000
Fair value of awards vested $ 17,000 95,000
Restricted Stock Units (RSUs) [Member] | Employees [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Vesting period 3 years  
Restricted Stock Units (RSUs) [Member] | Non Employee Members [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Vesting period 1 year  
Share-Based Payment Arrangement, Option [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Share-based compensation expense $ 6,000 $ 0
Share-Based Payment Arrangement, Option [Member] | Employees [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Vesting period 4 years  
Share-Based Payment Arrangement, Option [Member] | Board Of Directors [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Vesting period 1 year  
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Loss per Common Share (Details - Antidilutive shares) - shares
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive shares 5,533,561 618,333
Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive shares 10,061 177
Restricted Stock Units (RSUs) [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive shares 18,582 72,755
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive shares 5,504,918 545,401
EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�>L'W$P"POH[NK@JGKYX_ZZ&YNHU_?O4?OD!^AVU6\26GDI6<#+MJ=11\LBC9^WK>1 M'&GCC1AL+$F8A^8\7GQ'%> .FK0&>-B1A"]=6@2^=%#JL)RU5BWL6A+ MW6T@1D@Y3$@Y3$B.8QS!^

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�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end XML 43 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 44 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 46 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 72 164 1 false 24 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://phiopharma.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://phiopharma.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS' EQUITY (Unaudited) Sheet http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - Reconciliation of Cash and Restricted Cash Sheet http://phiopharma.com/role/ReconciliationOfCashAndRestrictedCash Reconciliation of Cash and Restricted Cash Statements 7 false false R8.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 8 false false R9.htm 995513 - Disclosure - Organization and Significant Accounting Policies Sheet http://phiopharma.com/role/OrganizationAndSignificantAccountingPolicies Organization and Significant Accounting Policies Notes 9 false false R10.htm 995514 - Disclosure - Collaboration Agreement Sheet http://phiopharma.com/role/CollaborationAgreement Collaboration Agreement Notes 10 false false R11.htm 995515 - Disclosure - Fair Value of Financial Instruments Sheet http://phiopharma.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 11 false false R12.htm 995516 - Disclosure - Leases Sheet http://phiopharma.com/role/Leases Leases Notes 12 false false R13.htm 995517 - Disclosure - Stockholders??? Equity Sheet http://phiopharma.com/role/StockholdersEquity Stockholders??? Equity Notes 13 false false R14.htm 995518 - Disclosure - Stock-based Compensation Sheet http://phiopharma.com/role/Stock-basedCompensation Stock-based Compensation Notes 14 false false R15.htm 995519 - Disclosure - Net Loss per Common Share Sheet http://phiopharma.com/role/NetLossPerCommonShare Net Loss per Common Share Notes 15 false false R16.htm 995520 - Disclosure - Organization and Significant Accounting Policies (Policies) Sheet http://phiopharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies Organization and Significant Accounting Policies (Policies) Policies http://phiopharma.com/role/OrganizationAndSignificantAccountingPolicies 16 false false R17.htm 995521 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://phiopharma.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://phiopharma.com/role/FairValueOfFinancialInstruments 17 false false R18.htm 995522 - Disclosure - Leases (Tables) Sheet http://phiopharma.com/role/LeasesTables Leases (Tables) Tables http://phiopharma.com/role/Leases 18 false false R19.htm 995523 - Disclosure - Stockholders??? Equity (Tables) Sheet http://phiopharma.com/role/StockholdersEquityTables Stockholders??? Equity (Tables) Tables http://phiopharma.com/role/StockholdersEquity 19 false false R20.htm 995524 - Disclosure - Stock-based Compensation (Tables) Sheet http://phiopharma.com/role/Stock-basedCompensationTables Stock-based Compensation (Tables) Tables http://phiopharma.com/role/Stock-basedCompensation 20 false false R21.htm 995525 - Disclosure - Net Loss per Common Share (Tables) Sheet http://phiopharma.com/role/NetLossPerCommonShareTables Net Loss per Common Share (Tables) Tables http://phiopharma.com/role/NetLossPerCommonShare 21 false false R22.htm 995526 - Disclosure - Collaboration Agreement (Details Narrative) Sheet http://phiopharma.com/role/CollaborationAgreementDetailsNarrative Collaboration Agreement (Details Narrative) Details http://phiopharma.com/role/CollaborationAgreement 22 false false R23.htm 995527 - Disclosure - Fair Value of Financial Instruments - (Details - Financial instruments at fair value) Sheet http://phiopharma.com/role/FairValueOfFinancialInstruments-Details-FinancialInstrumentsAtFairValue Fair Value of Financial Instruments - (Details - Financial instruments at fair value) Details http://phiopharma.com/role/FairValueOfFinancialInstrumentsTables 23 false false R24.htm 995528 - Disclosure - Leases (Details - Balance sheet lease items) Sheet http://phiopharma.com/role/LeasesDetails-BalanceSheetLeaseItems Leases (Details - Balance sheet lease items) Details http://phiopharma.com/role/LeasesTables 24 false false R25.htm 995529 - Disclosure - Leases (Details Narrative) Sheet http://phiopharma.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://phiopharma.com/role/LeasesTables 25 false false R26.htm 995530 - Disclosure - Stockholders' Equity (Details - Warrants outstanding) Sheet http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding Stockholders' Equity (Details - Warrants outstanding) Details 26 false false R27.htm 995531 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://phiopharma.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://phiopharma.com/role/StockholdersEquityTables 27 false false R28.htm 995532 - Disclosure - Stock-based Compensation (Details - RSU activity) Sheet http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity Stock-based Compensation (Details - RSU activity) Details http://phiopharma.com/role/Stock-basedCompensationTables 28 false false R29.htm 995533 - Disclosure - Stock-based Compensation (Details - Option activity) Sheet http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity Stock-based Compensation (Details - Option activity) Details http://phiopharma.com/role/Stock-basedCompensationTables 29 false false R30.htm 995534 - Disclosure - Stock-based Compensation (Details - Share-based compensation) Sheet http://phiopharma.com/role/Stock-basedCompensationDetails-Share-basedCompensation Stock-based Compensation (Details - Share-based compensation) Details http://phiopharma.com/role/Stock-basedCompensationTables 30 false false R31.htm 995535 - Disclosure - Stock-based Compensation (Details Narrative) Sheet http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative Stock-based Compensation (Details Narrative) Details http://phiopharma.com/role/Stock-basedCompensationTables 31 false false R32.htm 995536 - Disclosure - Net Loss per Common Share (Details - Antidilutive shares) Sheet http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares Net Loss per Common Share (Details - Antidilutive shares) Details http://phiopharma.com/role/NetLossPerCommonShareTables 32 false false All Reports Book All Reports phio-20240331.xsd phio-20240331_cal.xml phio-20240331_def.xml phio-20240331_lab.xml phio-20240331_pre.xml phio_i10q-033124.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 48 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "phio_i10q-033124.htm": { "nsprefix": "phio", "nsuri": "http://phiopharma.com/20240331", "dts": { "schema": { "local": [ "phio-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "phio-20240331_cal.xml" ] }, "definitionLink": { "local": [ "phio-20240331_def.xml" ] }, "labelLink": { "local": [ "phio-20240331_lab.xml" ] }, "presentationLink": { "local": [ "phio-20240331_pre.xml" ] }, "inline": { "local": [ "phio_i10q-033124.htm" ] } }, "keyStandard": 149, "keyCustom": 15, "axisStandard": 11, "axisCustom": 0, "memberStandard": 13, "memberCustom": 9, "hidden": { "total": 47, "http://fasb.org/us-gaap/2024": 38, "http://xbrl.sec.gov/dei/2024": 5, "http://phiopharma.com/20240331": 4 }, "contextCount": 72, "entityCount": 1, "segmentCount": 24, "elementCount": 363, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 294, "http://xbrl.sec.gov/dei/2024": 30 }, "report": { "R1": { "role": "http://phiopharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R2": { "role": "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets", "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R3": { "role": "http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R4": { "role": "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations", "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R5": { "role": "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity", "longName": "00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS' EQUITY (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS' EQUITY (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-12-31_custom_PreferredStockSeriesDMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_custom_PreferredStockSeriesDMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R6": { "role": "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows", "longName": "00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "unique": true } }, "R7": { "role": "http://phiopharma.com/role/ReconciliationOfCashAndRestrictedCash", "longName": "00000007 - Statement - Reconciliation of Cash and Restricted Cash", "shortName": "Reconciliation of Cash and Restricted Cash", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://phiopharma.com/role/OrganizationAndSignificantAccountingPolicies", "longName": "995513 - Disclosure - Organization and Significant Accounting Policies", "shortName": "Organization and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R10": { "role": "http://phiopharma.com/role/CollaborationAgreement", "longName": "995514 - Disclosure - Collaboration Agreement", "shortName": "Collaboration Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R11": { "role": "http://phiopharma.com/role/FairValueOfFinancialInstruments", "longName": "995515 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R12": { "role": "http://phiopharma.com/role/Leases", "longName": "995516 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R13": { "role": "http://phiopharma.com/role/StockholdersEquity", "longName": "995517 - Disclosure - Stockholders\u2019 Equity", "shortName": "Stockholders\u2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R14": { "role": "http://phiopharma.com/role/Stock-basedCompensation", "longName": "995518 - Disclosure - Stock-based Compensation", "shortName": "Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R15": { "role": "http://phiopharma.com/role/NetLossPerCommonShare", "longName": "995519 - Disclosure - Net Loss per Common Share", "shortName": "Net Loss per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R16": { "role": "http://phiopharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies", "longName": "995520 - Disclosure - Organization and Significant Accounting Policies (Policies)", "shortName": "Organization and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R17": { "role": "http://phiopharma.com/role/FairValueOfFinancialInstrumentsTables", "longName": "995521 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R18": { "role": "http://phiopharma.com/role/LeasesTables", "longName": "995522 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "phio:SupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "phio:SupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R19": { "role": "http://phiopharma.com/role/StockholdersEquityTables", "longName": "995523 - Disclosure - Stockholders\u2019 Equity (Tables)", "shortName": "Stockholders\u2019 Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R20": { "role": "http://phiopharma.com/role/Stock-basedCompensationTables", "longName": "995524 - Disclosure - Stock-based Compensation (Tables)", "shortName": "Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R21": { "role": "http://phiopharma.com/role/NetLossPerCommonShareTables", "longName": "995525 - Disclosure - Net Loss per Common Share (Tables)", "shortName": "Net Loss per Common Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R22": { "role": "http://phiopharma.com/role/CollaborationAgreementDetailsNarrative", "longName": "995526 - Disclosure - Collaboration Agreement (Details Narrative)", "shortName": "Collaboration Agreement (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "From2024-01-012024-03-31_custom_ClinicalCoDevelopmentAgreementMember_custom_AgonOxMember", "name": "phio:ExpenseFromContractualObligations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-03-31_custom_ClinicalCoDevelopmentAgreementMember_custom_AgonOxMember", "name": "phio:ExpenseFromContractualObligations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R23": { "role": "http://phiopharma.com/role/FairValueOfFinancialInstruments-Details-FinancialInstrumentsAtFairValue", "longName": "995527 - Disclosure - Fair Value of Financial Instruments - (Details - Financial instruments at fair value)", "shortName": "Fair Value of Financial Instruments - (Details - Financial instruments at fair value)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R24": { "role": "http://phiopharma.com/role/LeasesDetails-BalanceSheetLeaseItems", "longName": "995528 - Disclosure - Leases (Details - Balance sheet lease items)", "shortName": "Leases (Details - Balance sheet lease items)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "phio:SupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "unique": true } }, "R25": { "role": "http://phiopharma.com/role/LeasesDetailsNarrative", "longName": "995529 - Disclosure - Leases (Details Narrative)", "shortName": "Leases (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R26": { "role": "http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding", "longName": "995530 - Disclosure - Stockholders' Equity (Details - Warrants outstanding)", "shortName": "Stockholders' Equity (Details - Warrants outstanding)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_WarrantMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_WarrantMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R27": { "role": "http://phiopharma.com/role/StockholdersEquityDetailsNarrative", "longName": "995531 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "phio:WarrantsExercisedShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "phio:WarrantsExercisedShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R28": { "role": "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity", "longName": "995532 - Disclosure - Stock-based Compensation (Details - RSU activity)", "shortName": "Stock-based Compensation (Details - RSU activity)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R29": { "role": "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity", "longName": "995533 - Disclosure - Stock-based Compensation (Details - Option activity)", "shortName": "Stock-based Compensation (Details - Option activity)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_EmployeeStockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_EmployeeStockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } }, "R30": { "role": "http://phiopharma.com/role/Stock-basedCompensationDetails-Share-basedCompensation", "longName": "995534 - Disclosure - Stock-based Compensation (Details - Share-based compensation)", "shortName": "Stock-based Compensation (Details - Share-based compensation)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "unique": true } }, "R31": { "role": "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative", "longName": "995535 - Disclosure - Stock-based Compensation (Details Narrative)", "shortName": "Stock-based Compensation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-03-31_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "unique": true } }, "R32": { "role": "http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares", "longName": "995536 - Disclosure - Net Loss per Common Share (Details - Antidilutive shares)", "shortName": "Net Loss per Common Share (Details - Antidilutive shares)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "phio_i10q-033124.htm", "first": true, "unique": true } } }, "tag": { "phio_AbeyanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "AbeyanceSharesMember", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Abeyance Shares [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24", "r414" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r472" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r30", "r414", "r547" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r317", "r523", "r524", "r525", "r526", "r536", "r548" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r478" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r478" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r478" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r478" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Shares withheld for payroll taxes", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r21", "r22", "r186" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit", "crdr": "debit", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Cash-in-lieu of fractional shares for reverse stock split", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately." } } }, "auth_ref": [ "r4", "r50" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r443", "r454", "r464", "r489" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r446", "r457", "r467", "r492" ] }, "phio_AgonOxMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "AgonOxMember", "presentation": [ "http://phiopharma.com/role/CollaborationAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Agon Ox [Member]" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r478" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r485" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r447", "r458", "r468", "r485", "r493", "r497", "r505" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "auth_ref": [ "r503" ] }, "phio_AmendedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "AmendedWarrants", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "[custom:AmendedWarrants]" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r450" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares" ], "lang": { "en-us": { "role": { "label": "Antidilutive shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r120" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r8" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r8" ] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfRealEstateProperty", "presentation": [ "http://phiopharma.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating lease footage", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets [Default Label]", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r54", "r59", "r78", "r94", "r124", "r128", "r137", "r138", "r142", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r229", "r231", "r264", "r293", "r350", "r398", "r399", "r414", "r424", "r534", "r535", "r540" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r74", "r82", "r94", "r142", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r229", "r231", "r264", "r414", "r534", "r535", "r540" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "phio_AssetsLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "AssetsLesseeAbstract", "presentation": [ "http://phiopharma.com/role/LeasesDetails-BalanceSheetLeaseItems" ], "lang": { "en-us": { "role": { "label": "Assets" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r450" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": [ "r500" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r501" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "auth_ref": [ "r496" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r496" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method" } } }, "auth_ref": [ "r496" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r496" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r496" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined" } } }, "auth_ref": [ "r496" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity", "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity", "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative", "http://phiopharma.com/role/StockholdersEquityDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Securities" } } }, "auth_ref": [ "r499" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r498" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r497" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r497" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://phiopharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "phio_BoardOfDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "BoardOfDirectorsMember", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Board Of Directors [Member]" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "calculation": { "http://phiopharma.com/role/ReconciliationOfCashAndRestrictedCash": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://phiopharma.com/role/ReconciliationOfCashAndRestrictedCash" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r61", "r295", "r328", "r345", "r414", "r424", "r515" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r7", "r76", "r389" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://phiopharma.com/role/FairValueOfFinancialInstruments-Details-FinancialInstrumentsAtFairValue" ], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r537", "r538" ] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://phiopharma.com/role/FairValueOfFinancialInstruments-Details-FinancialInstrumentsAtFairValue" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://phiopharma.com/role/ReconciliationOfCashAndRestrictedCash": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://phiopharma.com/role/ReconciliationOfCashAndRestrictedCash" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of period", "totalLabel": "Cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r7", "r39", "r91" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net decrease in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r39" ] }, "phio_CashInLieuOfFractionalSharesForReverseStockSplit": { "xbrltype": "monetaryItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "CashInLieuOfFractionalSharesForReverseStockSplit", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash in lieu of fractional shares for reverse stock split", "label": "CashInLieuOfFractionalSharesForReverseStockSplit" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r476" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r71", "r79", "r80", "r81", "r94", "r114", "r115", "r117", "r119", "r126", "r127", "r142", "r149", "r151", "r152", "r153", "r156", "r157", "r162", "r163", "r166", "r169", "r176", "r264", "r312", "r313", "r314", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r329", "r337", "r359", "r377", "r382", "r383", "r384", "r385", "r386", "r513", "r520", "r527" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding", "http://phiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r79", "r80", "r81", "r126", "r162", "r163", "r164", "r166", "r169", "r174", "r176", "r312", "r313", "r314", "r315", "r403", "r513", "r520" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants outstanding, beginning", "periodEndLabel": "Warrants outstanding", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "phio_ClassOfWarrantOrRightWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "ClassOfWarrantOrRightWeightedAverageExercisePrice", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants outstanding, weighted average exercise price", "periodEndLabel": "Warrants outstanding, weighted average exercise price", "label": "ClassOfWarrantOrRightWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "phio_ClinicalCoDevelopmentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "ClinicalCoDevelopmentAgreementMember", "presentation": [ "http://phiopharma.com/role/CollaborationAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Clinical Co Development Agreement [Member]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r477" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r477" ] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://phiopharma.com/role/CollaborationAgreement" ], "lang": { "en-us": { "role": { "label": "Collaboration Agreement", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r63", "r65", "r70" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://phiopharma.com/role/CollaborationAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r228" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note 2)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r27", "r55", "r294", "r336" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r29" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r415", "r416", "r417", "r419", "r420", "r421", "r422", "r523", "r524", "r526", "r536", "r546", "r548" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r29" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r29", "r337" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares, issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r29" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r4", "r29", "r337", "r356", "r548", "r549" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.0001 par value, 100,000,000 shares authorized; 4,591,700 and 3,747,329 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r29", "r297", "r414" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r482" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r481" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r483" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r480" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://phiopharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r23", "r393" ] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualObligation", "crdr": "credit", "presentation": [ "http://phiopharma.com/role/CollaborationAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Contractual obligation", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": [ "r522" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://phiopharma.com/role/CollaborationAgreementDetailsNarrative", "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r95", "r96", "r158", "r164", "r283", "r287", "r292", "r390", "r392" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "phio_December2023FinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "December2023FinancingMember", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "December 2023 Financing [Member]" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r2", "r124", "r129", "r138", "r398", "r399" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensation" ], "lang": { "en-us": { "role": { "label": "Stock-based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r184", "r188", "r215", "r216", "r217", "r407" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r438" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r436", "r438", "r450" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r437" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r425" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r438" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r438" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r471" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r428" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per common share:", "verboseLabel": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per common share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r88", "r102", "r103", "r104", "r105", "r106", "r107", "r112", "r114", "r117", "r118", "r119", "r123", "r224", "r227", "r241", "r242", "r290", "r303", "r394" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per common share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r88", "r102", "r103", "r104", "r105", "r106", "r107", "r114", "r117", "r118", "r119", "r123", "r224", "r227", "r241", "r242", "r290", "r303", "r394" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://phiopharma.com/role/NetLossPerCommonShare" ], "lang": { "en-us": { "role": { "label": "Net Loss per Common Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r111", "r120", "r121", "r122" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-Share-basedCompensation" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity", "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "phio_EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "EmployeesMember", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employees [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r431" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r427" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r427" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r512" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r427" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r509" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r450" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r427" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r427" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r427" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r427" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r510" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r4", "r72", "r85", "r86", "r87", "r97", "r98", "r99", "r101", "r106", "r108", "r110", "r125", "r143", "r144", "r145", "r177", "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r227", "r233", "r234", "r235", "r236", "r237", "r238", "r240", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r282", "r302", "r306", "r307", "r308", "r317", "r377" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r479" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r443", "r454", "r464", "r489" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r440", "r451", "r461", "r486" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r485" ] }, "phio_ExpenseFromContractualObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "ExpenseFromContractualObligations", "crdr": "debit", "presentation": [ "http://phiopharma.com/role/CollaborationAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expense from contractual obligations" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://phiopharma.com/role/FairValueOfFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of financial instruments at fair value", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r537", "r538" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://phiopharma.com/role/FairValueOfFinancialInstruments-Details-FinancialInstrumentsAtFairValue" ], "lang": { "en-us": { "role": { "documentation": "Class of asset." } } }, "auth_ref": [ "r248", "r249", "r250", "r251", "r252", "r253", "r258", "r409" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://phiopharma.com/role/FairValueOfFinancialInstruments-Details-FinancialInstrumentsAtFairValue" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r248", "r249", "r250", "r251", "r252", "r253", "r258", "r409" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://phiopharma.com/role/FairValueOfFinancialInstruments-Details-FinancialInstrumentsAtFairValue" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument asset measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": [ "r248", "r249", "r250", "r251", "r252", "r253", "r258", "r409" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://phiopharma.com/role/FairValueOfFinancialInstruments-Details-FinancialInstrumentsAtFairValue" ], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r248", "r249", "r250", "r251", "r252", "r253", "r258", "r409" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://phiopharma.com/role/FairValueOfFinancialInstruments-Details-FinancialInstrumentsAtFairValue" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r159", "r178", "r179", "r180", "r181", "r182", "r183", "r243", "r244", "r245", "r246", "r247", "r256", "r257", "r259", "r284", "r285", "r286", "r401", "r402", "r404", "r405", "r406", "r408", "r411" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://phiopharma.com/role/FairValueOfFinancialInstruments" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r252", "r254", "r255", "r256", "r259", "r260", "r261", "r262", "r263", "r289", "r408", "r412" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://phiopharma.com/role/FairValueOfFinancialInstruments-Details-FinancialInstrumentsAtFairValue" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r159", "r178", "r183", "r244", "r257", "r284", "r404", "r405", "r406", "r408" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://phiopharma.com/role/FairValueOfFinancialInstruments-Details-FinancialInstrumentsAtFairValue" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r159", "r178", "r183", "r244", "r245", "r257", "r285", "r401", "r402", "r404", "r405", "r406", "r408" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://phiopharma.com/role/FairValueOfFinancialInstruments-Details-FinancialInstrumentsAtFairValue" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r159", "r178", "r179", "r180", "r181", "r182", "r183", "r244", "r245", "r246", "r247", "r257", "r286", "r401", "r402", "r404", "r405", "r406", "r408", "r411" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://phiopharma.com/role/FairValueOfFinancialInstruments-Details-FinancialInstrumentsAtFairValue" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r159", "r178", "r179", "r180", "r181", "r182", "r183", "r243", "r244", "r245", "r246", "r247", "r256", "r257", "r259", "r284", "r285", "r286", "r401", "r402", "r404", "r405", "r406", "r408", "r411" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r447", "r458", "r468", "r493" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r447", "r458", "r468", "r493" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r447", "r458", "r468", "r493" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r447", "r458", "r468", "r493" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r447", "r458", "r468", "r493" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal of property and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r2" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r36", "r361" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-Share-basedCompensation" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r36" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-Share-basedCompensation" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r146", "r147", "r148", "r249", "r253", "r258", "r304", "r305", "r362", "r388", "r410", "r545" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-Share-basedCompensation" ], "lang": { "en-us": { "role": { "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r147", "r148", "r249", "r253", "r258", "r304", "r305", "r362", "r388", "r410", "r545" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r1" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r1" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease liability", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r514", "r517" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r1" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": [ "r447", "r458", "r468", "r485", "r493", "r497", "r505" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": [ "r503" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r439", "r508" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r439", "r508" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r439", "r508" ] }, "us-gaap_LeaseAndRentalExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseAndRentalExpense", "crdr": "debit", "presentation": [ "http://phiopharma.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total base rent", "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseExpirationDate1", "presentation": [ "http://phiopharma.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease expiration date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "phio_LeaseTermAndDiscountRateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "LeaseTermAndDiscountRateAbstract", "presentation": [ "http://phiopharma.com/role/LeasesDetails-BalanceSheetLeaseItems" ], "lang": { "en-us": { "role": { "label": "Lease Term and Discount Rate" } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://phiopharma.com/role/Leases" ], "lang": { "en-us": { "role": { "label": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r272" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r34", "r56", "r299", "r414", "r521", "r533", "r539" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r26", "r75", "r94", "r142", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r230", "r231", "r232", "r264", "r414", "r534", "r540", "r541" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "phio_LiabilitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "LiabilitiesLesseeAbstract", "presentation": [ "http://phiopharma.com/role/LeasesDetails-BalanceSheetLeaseItems" ], "lang": { "en-us": { "role": { "label": "Liabilities" } } }, "auth_ref": [] }, "phio_LiquidityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "LiquidityPolicyTextBlock", "presentation": [ "http://phiopharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Liquidity" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": [ "r477" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": [ "r477" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r496" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r504" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r478" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": [ "http://phiopharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Nature of Operations", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r62", "r69" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net cash used in financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r90" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r39", "r40", "r41" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations", "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "verboseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r35", "r41", "r57", "r73", "r83", "r84", "r87", "r94", "r100", "r102", "r103", "r104", "r105", "r106", "r109", "r110", "r116", "r142", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r224", "r227", "r242", "r264", "r301", "r358", "r375", "r376", "r423", "r534" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://phiopharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "phio_NonEmployeeMembersMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "NonEmployeeMembersMember", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non Employee Members [Member]" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r477" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r475" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r474" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r504" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r504" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Total other income, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r37" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r58", "r395", "r528", "r529", "r530", "r531", "r532" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://phiopharma.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating lease costs", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r277", "r413" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://phiopharma.com/role/LeasesDetails-BalanceSheetLeaseItems" ], "lang": { "en-us": { "role": { "label": "Total lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r275" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r275" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://phiopharma.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating lease payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r276", "r278" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets", "http://phiopharma.com/role/LeasesDetails-BalanceSheetLeaseItems" ], "lang": { "en-us": { "role": { "label": "Right of use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r274" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of right of use asset", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r518" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://phiopharma.com/role/LeasesDetails-BalanceSheetLeaseItems" ], "lang": { "en-us": { "role": { "label": "Weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r280", "r413" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://phiopharma.com/role/LeasesDetails-BalanceSheetLeaseItems" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r279", "r413" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://phiopharma.com/role/OrganizationAndSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Organization and Significant Accounting Policies", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r42", "r43", "r44", "r52" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r77" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r477" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r438" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r445", "r456", "r466", "r491" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": [ "r448", "r459", "r469", "r494" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r448", "r459", "r469", "r494" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": [ "r473" ] }, "us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfRedeemablePreferredStock", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Redemption of Series D preferred stock", "label": "Payments for Repurchase of Redeemable Preferred Stock", "documentation": "The cash outflow for reacquisition of callable preferred stock." } } }, "auth_ref": [ "r38" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of taxes on net share settlements of restricted stock units", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r89" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r476" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r476" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r475" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": [ "r478" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r474" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r475" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r432" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r434" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r28", "r162" ] }, "phio_PreferredStockSeriesDMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "PreferredStockSeriesDMember", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Series D [Member]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r28", "r337" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares, issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r28", "r162" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r28", "r337", "r356", "r548", "r549" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.0001 par value, 100,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r28", "r296", "r414" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r516" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r3", "r281", "r291", "r300", "r414" ] }, "us-gaap_PropertySubjectToOperatingLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertySubjectToOperatingLeaseMember", "presentation": [ "http://phiopharma.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property Subject to Operating Lease [Member]", "documentation": "Property subject to an operating lease." } } }, "auth_ref": [] }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis", "presentation": [ "http://phiopharma.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property Subject to or Available for Operating Lease [Axis]", "documentation": "Information by property that could be leased or is available for lease." } } }, "auth_ref": [ "r60" ] }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain", "presentation": [ "http://phiopharma.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "A descriptive title of whether the property is subject to or available for operating lease." } } }, "auth_ref": [ "r60" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r473" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r473" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": [ "r440", "r451", "r461", "r486" ] }, "phio_RedemptionOfPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "RedemptionOfPreferredStock", "crdr": "credit", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Redemption of preferred stock" } } }, "auth_ref": [] }, "phio_RedemptionOfPreferredStockShares": { "xbrltype": "sharesItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "RedemptionOfPreferredStockShares", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Redemption of preferred stock, shares" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://phiopharma.com/role/CollaborationAgreementDetailsNarrative", "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "auth_ref": [ "r95", "r96", "r158", "r164", "r283", "r287", "r292", "r391", "r392" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r218", "r388", "r398", "r542" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-Share-basedCompensation" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r441", "r452", "r462", "r487" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": [ "r442", "r453", "r463", "r488" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": [ "r449", "r460", "r470", "r495" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://phiopharma.com/role/ReconciliationOfCashAndRestrictedCash": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://phiopharma.com/role/ReconciliationOfCashAndRestrictedCash" ], "lang": { "en-us": { "role": { "label": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r515", "r519", "r543", "r544" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares", "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity", "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r31", "r50", "r298", "r309", "r310", "r316", "r338", "r414" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r72", "r97", "r98", "r99", "r101", "r106", "r108", "r110", "r143", "r144", "r145", "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r227", "r233", "r235", "r236", "r238", "r240", "r271", "r273", "r306", "r308", "r317", "r548" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r504" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r504" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://phiopharma.com/role/NetLossPerCommonShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of anti dilutive stock", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://phiopharma.com/role/CollaborationAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r228" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-Share-basedCompensation" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of stock-based compensation expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity", "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity", "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r185", "r187", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Summary of RSU activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r51" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Summary of stock option activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r5", "r6", "r51" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r12", "r13", "r14", "r15", "r16", "r17", "r46", "r48", "r49", "r50", "r79", "r80", "r81", "r126", "r162", "r163", "r164", "r166", "r169", "r174", "r176", "r312", "r313", "r314", "r315", "r403", "r513", "r520" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://phiopharma.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of outstanding warrants", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r18" ] }, "us-gaap_SecuritiesFinancingTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesFinancingTransactionAxis", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Securities Financing Transaction [Axis]", "documentation": "Information by type of securities financing transactions, including, but not limited to those measured at fair value or cost." } } }, "auth_ref": [ "r53" ] }, "us-gaap_SecuritiesFinancingTransactionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesFinancingTransactionTable", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Security Financing Transaction [Table]", "documentation": "Disclosure of information about security financing transaction by measurement type." } } }, "auth_ref": [ "r53" ] }, "us-gaap_SecuritiesFinancingTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesFinancingTransactionTypeDomain", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Measurement of financing transaction securities held." } } }, "auth_ref": [ "r53" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r426" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r430" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r429" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r435" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://phiopharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segments", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r139", "r140", "r396", "r397", "r400" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://phiopharma.com/role/Stock-basedCompensationDetails-Share-basedCompensation", "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "verboseLabel": "Total stock-based compensation", "terseLabel": "Share-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r407" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity" ], "lang": { "en-us": { "role": { "negatedLabel": "RSU's forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r205" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity" ], "lang": { "en-us": { "role": { "label": "RSU's forfeited, price per share", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r205" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity" ], "lang": { "en-us": { "role": { "label": "RSU's granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r203" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity", "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "RSU's granted, price per share", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r203" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity" ], "lang": { "en-us": { "role": { "periodStartLabel": "RSU's unvested units, beginning balance", "periodEndLabel": "RSU's unvested units, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r200", "r201" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity" ], "lang": { "en-us": { "role": { "periodStartLabel": "RSU beginning balance, price per share", "periodEndLabel": "RSU ending balance, price per share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r200", "r201" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity" ], "lang": { "en-us": { "role": { "negatedLabel": "RSU's vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r204" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of awards vested", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r207" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity" ], "lang": { "en-us": { "role": { "label": "RSU's vested, price per share", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r204" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity", "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity", "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r185", "r187", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity" ], "lang": { "en-us": { "role": { "label": "Number of shares outstanding, Exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r194" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price per share, Exercisable", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r194" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of shares outstanding, Expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r199" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity" ], "lang": { "en-us": { "role": { "label": "Number of shares outstanding, Forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r198" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity" ], "lang": { "en-us": { "role": { "label": "Number of shares outstanding, Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r196" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity" ], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value, Outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of shares outstanding, Beginning", "periodEndLabel": "Number of shares outstanding, Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r192", "r193" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price per share, Beginning", "periodEndLabel": "Weighted average exercise price per share, Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r192", "r193" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity", "http://phiopharma.com/role/Stock-basedCompensationDetails-RsuActivity", "http://phiopharma.com/role/Stock-basedCompensationDetailsNarrative", "http://phiopharma.com/role/StockholdersEquityDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price per share, Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r197" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price per share, Expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r199" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price per share, Forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r198" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price per share, Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r196" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity" ], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value, Exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r19" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning, shares", "periodEndLabel": "Balance at ending, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Shares withheld for payroll taxes, shares", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://phiopharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r42", "r92" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r433" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r71", "r79", "r80", "r81", "r94", "r114", "r115", "r117", "r119", "r126", "r127", "r142", "r149", "r151", "r152", "r153", "r156", "r157", "r162", "r163", "r166", "r169", "r176", "r264", "r312", "r313", "r314", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r329", "r337", "r359", "r377", "r382", "r383", "r384", "r385", "r386", "r513", "r520", "r527" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r4", "r29", "r32", "r33", "r72", "r85", "r86", "r87", "r97", "r98", "r99", "r101", "r106", "r108", "r110", "r125", "r143", "r144", "r145", "r177", "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r227", "r233", "r234", "r235", "r236", "r237", "r238", "r240", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r282", "r302", "r306", "r307", "r308", "r317", "r377" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity", "http://phiopharma.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r97", "r98", "r99", "r125", "r273", "r288", "r311", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r337", "r340", "r341", "r342", "r343", "r344", "r346", "r347", "r348", "r349", "r351", "r352", "r353", "r354", "r355", "r357", "r360", "r361", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r377", "r418" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity", "http://phiopharma.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r97", "r98", "r99", "r125", "r141", "r273", "r288", "r311", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r337", "r340", "r341", "r342", "r343", "r344", "r346", "r347", "r348", "r349", "r351", "r352", "r353", "r354", "r355", "r357", "r360", "r361", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r377", "r418" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r444", "r455", "r465", "r490" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon exercise of warrants, shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r4", "r14", "r29", "r32", "r50", "r160" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon vesting of restricted stock units, shares", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r4", "r28", "r29", "r50" ] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Cash-in-lieu of fractional shares for reverse stock split, shares", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": [ "r4" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://phiopharma.com/role/Stock-basedCompensationDetails-OptionActivity" ], "lang": { "en-us": { "role": { "label": "Number of shares outstanding, Exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r4", "r28", "r29", "r50", "r197" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon exercise of warrants", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r4", "r29", "r32", "r33", "r50" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon vesting of restricted stock units", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r4", "r50" ] }, "phio_StockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "StockOptionsMember", "presentation": [ "http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares" ], "lang": { "en-us": { "role": { "label": "Stock Options [Member]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets", "http://phiopharma.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r29", "r32", "r33", "r45", "r339", "r356", "r378", "r379", "r414", "r424", "r521", "r533", "r539", "r548" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://phiopharma.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r47", "r93", "r161", "r163", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r175", "r177", "r239", "r380", "r381", "r387" ] }, "phio_SupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "SupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock", "presentation": [ "http://phiopharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of lease amounts recorded in balance sheet" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth_ref": [ "r484" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r476" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r483" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r503" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r505" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransactionDomain", "presentation": [ "http://phiopharma.com/role/CollaborationAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r392" ] }, "us-gaap_TransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransactionTypeAxis", "presentation": [ "http://phiopharma.com/role/CollaborationAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Transaction Type [Axis]", "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r392" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": [ "r506" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": [ "r507" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": [ "r507" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r505" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": [ "r505" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": [ "r506" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r502" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://phiopharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r9", "r10", "r11", "r64", "r66", "r67", "r68" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://phiopharma.com/role/NetLossPerCommonShareDetails-AntidilutiveShares", "http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r415", "r416", "r419", "r420", "r421", "r422" ] }, "phio_WarrantsExercisedShare": { "xbrltype": "sharesItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "WarrantsExercisedShare", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "negatedLabel": "Warrants exercised, shares", "label": "WarrantsExercisedShare" } } }, "auth_ref": [] }, "phio_WarrantsExercisedShares": { "xbrltype": "sharesItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "WarrantsExercisedShares", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants exercised shares" } } }, "auth_ref": [] }, "phio_WarrantsExercisedWeightedAverageExercisePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "WarrantsExercisedWeightedAverageExercisePricePerShare", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "label": "Warrants exercised, weighted average exercise price" } } }, "auth_ref": [] }, "phio_WarrantsExpiredShares": { "xbrltype": "sharesItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "WarrantsExpiredShares", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "negatedLabel": "Warrants expired, shares", "label": "WarrantsExpiredShares" } } }, "auth_ref": [] }, "phio_WarrantsExpiredWeightedAverageExercisePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "WarrantsExpiredWeightedAverageExercisePricePerShare", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "label": "Warrants expired, weighted average exercise price" } } }, "auth_ref": [] }, "phio_WarrantsIssuedShares": { "xbrltype": "sharesItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "WarrantsIssuedShares", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "label": "Warrants issued, shares" } } }, "auth_ref": [] }, "phio_WarrantsIssuedWeightedAverageExercisePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://phiopharma.com/20240331", "localname": "WarrantsIssuedWeightedAverageExercisePricePerShare", "presentation": [ "http://phiopharma.com/role/StockholdersEquityDetails-WarrantsOutstanding" ], "lang": { "en-us": { "role": { "label": "Warrants issued, weighted average exercise price" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r113", "r119" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://phiopharma.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r112", "r119" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://phiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r511" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-4" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r391": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r392": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r393": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r394": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r395": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r396": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r397": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r398": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r399": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r400": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r401": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r402": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r403": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r404": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r407": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r409": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r410": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r411": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r412": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r413": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r414": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r415": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r417": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r424": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r425": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r426": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r427": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r429": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r431": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r432": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r433": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r434": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r435": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r436": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r437": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r438": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r439": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r440": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r441": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r442": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r443": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r444": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r445": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r446": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r447": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r448": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r449": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r450": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r451": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r452": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r453": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r454": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r455": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r456": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r457": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r458": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r459": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r460": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r461": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r462": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r463": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r464": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r465": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r466": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r467": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r468": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r469": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r470": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r471": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r473": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r474": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r475": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r476": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r477": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r478": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r479": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r480": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r481": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r482": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r483": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r484": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r485": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r486": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r487": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r488": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r489": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r490": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r491": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r492": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r493": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r494": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r495": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r496": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r497": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r498": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r499": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r500": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r506": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r508": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r509": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r510": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r511": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r512": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r513": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 49 0001683168-24-003175-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-24-003175-xbrl.zip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�&V, VH@&'X;T5:!,M'!#U0'E&*H."BM9WE.1^3>#C:^&L_

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end XML 51 phio_i10q-033124_htm.xml IDEA: XBRL DOCUMENT 0001533040 2024-01-01 2024-03-31 0001533040 2024-05-03 0001533040 2024-03-31 0001533040 2023-12-31 0001533040 2023-01-01 2023-03-31 0001533040 phio:PreferredStockSeriesDMember 2023-12-31 0001533040 us-gaap:CommonStockMember 2023-12-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001533040 us-gaap:RetainedEarningsMember 2023-12-31 0001533040 phio:PreferredStockSeriesDMember 2022-12-31 0001533040 us-gaap:CommonStockMember 2022-12-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001533040 us-gaap:RetainedEarningsMember 2022-12-31 0001533040 2022-12-31 0001533040 phio:PreferredStockSeriesDMember 2024-01-01 2024-03-31 0001533040 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001533040 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001533040 phio:PreferredStockSeriesDMember 2023-01-01 2023-03-31 0001533040 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001533040 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001533040 phio:PreferredStockSeriesDMember 2024-03-31 0001533040 us-gaap:CommonStockMember 2024-03-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001533040 us-gaap:RetainedEarningsMember 2024-03-31 0001533040 phio:PreferredStockSeriesDMember 2023-03-31 0001533040 us-gaap:CommonStockMember 2023-03-31 0001533040 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001533040 us-gaap:RetainedEarningsMember 2023-03-31 0001533040 2023-03-31 0001533040 phio:AgonOxMember phio:ClinicalCoDevelopmentAgreementMember 2024-01-01 2024-03-31 0001533040 phio:AgonOxMember phio:ClinicalCoDevelopmentAgreementMember 2023-01-01 2023-03-31 0001533040 phio:AgonOxMember phio:ClinicalCoDevelopmentAgreementMember 2023-12-31 0001533040 us-gaap:CashAndCashEquivalentsMember 2024-03-31 0001533040 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2024-03-31 0001533040 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2024-03-31 0001533040 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2024-03-31 0001533040 us-gaap:FairValueInputsLevel1Member 2024-03-31 0001533040 us-gaap:FairValueInputsLevel2Member 2024-03-31 0001533040 us-gaap:FairValueInputsLevel3Member 2024-03-31 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember 2024-03-31 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember 2024-01-01 2024-03-31 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember 2024-03-01 0001533040 us-gaap:PropertySubjectToOperatingLeaseMember 2024-02-29 2024-03-01 0001533040 phio:December2023FinancingMember 2023-01-01 2023-12-31 0001533040 phio:AbeyanceSharesMember 2023-12-31 0001533040 us-gaap:WarrantMember 2023-12-31 0001533040 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001533040 us-gaap:WarrantMember 2024-03-31 0001533040 phio:EmployeesMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001533040 phio:NonEmployeeMembersMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001533040 phio:EmployeesMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001533040 phio:BoardOfDirectorsMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001533040 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001533040 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001533040 us-gaap:EmployeeStockOptionMember 2023-12-31 0001533040 us-gaap:EmployeeStockOptionMember 2024-03-31 0001533040 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001533040 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001533040 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001533040 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001533040 phio:StockOptionsMember 2024-01-01 2024-03-31 0001533040 phio:StockOptionsMember 2023-01-01 2023-03-31 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001533040 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001533040 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001533040 us-gaap:WarrantMember 2023-01-01 2023-03-31 iso4217:USD shares iso4217:USD shares pure utr:sqft false --12-31 2024 Q1 0001533040 10-Q true 2024-03-31 false 001-36304 Phio Pharmaceuticals Corp. DE 45-3215903 11 Apex Drive Suite 300A, PMB 2006 Marlborough MA 01752 508 767-3861 Common Stock, par value, $0.0001 per share PHIO NASDAQ Yes Yes Non-accelerated Filer true false false 4591700 6475000 8490000 373000 832000 6848000 9322000 0 33000 2000 6000 3000 3000 6853000 9364000 320000 657000 929000 942000 0 35000 1249000 1634000 0.0001 0.0001 100000000 100000000 0 0 0 0 0 0 0.0001 0.0001 100000000 100000000 4591700 4591700 3747329 3747329 0 0 146964000 146936000 -141360000 -139206000 5604000 7730000 6853000 9364000 1148000 2134000 1061000 1468000 2209000 3602000 -2209000 -3602000 55000 0 -2154000 -3602000 -0.47 -0.47 -3.15 -3.15 4580072 4580072 1142213 1142213 0 0 3747329 0 146936000 -139206000 7730000 826370 24198 6197 4000 4000 32000 32000 -2154000 -2154000 0 0 4591700 0 146964000 -141360000 5604000 1 2000 1139024 0 139218000 -128380000 10838000 -1706 -11000 -11000 -1 -2000 18080 4816 25000 25000 111000 111000 -3602000 -3602000 0 0 1150582 0 139293000 -131982000 7311000 -2154000 -3602000 1000 16000 33000 31000 -3000 -0 32000 111000 -459000 -314000 -337000 123000 -13000 331000 -35000 -32000 -2011000 -2708000 -0 11000 -0 2000 4000 25000 -4000 -38000 -2015000 -2746000 8490000 11831000 6475000 9085000 6475000 9035000 0 50000 6475000 9085000 <p id="xdx_804_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zNp95n7eRoLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. <span id="xdx_82F_zrjFxl2aaQZg">Organization and Significant Accounting Policies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_847_eus-gaap--NatureOfOperations_zC5CkoJL95C8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86B_ztzn1J6AQqK9">Nature of Operations</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Phio Pharmaceuticals Corp. (“<b>Phio</b>” or the “<b>Company</b>”) is a clinical stage biotechnology company whose proprietary INTASYL™ small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Phio was incorporated in the state of Delaware in 2011 as RXi Pharmaceuticals Corporation. On November 19, 2018, the Company changed its name to Phio Pharmaceuticals Corp., to reflect its transition from a platform company to one that is fully committed to developing groundbreaking immuno-oncology therapeutics.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zPuqHYzCGdb4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_860_z2vLtm7hPdoa">Basis of Presentation </span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States (“<b>GAAP</b>”). Certain information and footnote disclosures that are included in the Company’s annual consolidated financial statements, but that are not required for interim reporting purposes, have been condensed or omitted. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “<b>SEC</b>”) on April 1, 2024 (the “<b>2023 Form 10-K</b>”). Interim results are not necessarily indicative of results for a full year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zX1rwFEd1zx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zrbq3Bn0g7Qd">Principles of Consolidation</span> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, MirImmune, LLC. All material intercompany accounts have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zCfYXp261ahl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i><span id="xdx_860_zpYFulhexe5f">Segments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>The Company operates as one operating segment and all assets are located in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_84B_eus-gaap--UseOfEstimates_zqQtde0hG5g5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zo2ZKVnrJDy8">Use of Estimates </span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas subject to significant estimates and judgement include, among others, those related to the fair value of equity awards, accruals for research and development expenses, useful lives of property and equipment, and the valuation allowance on the Company’s deferred tax assets. On an ongoing basis the Company evaluates its estimates and bases its estimates on historical experience and other relevant assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p id="xdx_84C_ecustom--LiquidityPolicyTextBlock_zmPfnoisd6dc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_862_zcPQT30mC2Qb">Liquidity</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has reported recurring losses from operations since its inception and expects to continue to have negative cash flows from operations for the foreseeable future. Historically, the Company’s primary source of funding has been from sales of its securities. The Company’s ability to continue to fund its operations is dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, or strategic opportunities, in order to maintain its operations. This is dependent on a number of factors, including the market demand or liquidity of the Company’s common stock. There is no guarantee that debt, additional equity or other funding will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, the Company would be forced to scale back or terminate its operations or seek to merge with or to be acquired by another company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has limited cash resources, has reported recurring losses from operations since inception, has negative operating cash flows and has not yet received product revenues. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern, and the Company’s current cash resources may not provide sufficient capital to fund operations for at least the next 12 months from the date of the release of these condensed consolidated financial statements. The continuation of the Company as a going concern depends upon the Company’s ability to raise additional capital through an equity offering, debt offering and/or strategic opportunity to fund its operations. There can be no assurance that the Company will be successful in accomplishing these plans in order to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--SignificantAccountingPoliciesTextBlock_zEIUB4E5HTf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86A_zUty3VkhORql">Summary of Significant Accounting Policies</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cash and Cash Equivalents </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash and cash equivalents include unrestricted cash accounts, money market investments and highly liquid investment instruments with original maturity of three months or less at the date of purchase.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than as set forth above, there have been no material changes to the significant accounting policies disclosed in the Company’s 2023 Form 10-K.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z1ml9UHzzpJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2023, the Financial Accounting Standards Board (the “<b>FASB</b>”) issued Accounting Standards Update (“<b>ASU</b>”) 2023-07, “Segment Reporting (Topic 280) – Improvements to Reporting Segment Disclosures” (“<b>ASU 2023-07</b>”), which requires disclosure of incremental segment information on an annual and interim basis. In addition, ASU 2023-07 clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and contains other disclosure requirements. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The enhanced disclosures are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of ASU 2023-07 on its consolidated financial statements and disclosures, but does not expect that it will have a material impact on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740) – Improvements to Income Tax Disclosures” (“ASU 2023-09”), which requires disclosure of specific categories in the rate reconciliation table along with additional information for reconciling items that meet a quantitative threshold, disclosure of disaggregated income taxes paid and modifies other income tax-related disclosures. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-09, but does not expect that it will have a material impact on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_847_eus-gaap--NatureOfOperations_zC5CkoJL95C8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86B_ztzn1J6AQqK9">Nature of Operations</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Phio Pharmaceuticals Corp. (“<b>Phio</b>” or the “<b>Company</b>”) is a clinical stage biotechnology company whose proprietary INTASYL™ small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Phio was incorporated in the state of Delaware in 2011 as RXi Pharmaceuticals Corporation. On November 19, 2018, the Company changed its name to Phio Pharmaceuticals Corp., to reflect its transition from a platform company to one that is fully committed to developing groundbreaking immuno-oncology therapeutics.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zPuqHYzCGdb4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_860_z2vLtm7hPdoa">Basis of Presentation </span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States (“<b>GAAP</b>”). Certain information and footnote disclosures that are included in the Company’s annual consolidated financial statements, but that are not required for interim reporting purposes, have been condensed or omitted. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “<b>SEC</b>”) on April 1, 2024 (the “<b>2023 Form 10-K</b>”). Interim results are not necessarily indicative of results for a full year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zX1rwFEd1zx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zrbq3Bn0g7Qd">Principles of Consolidation</span> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, MirImmune, LLC. All material intercompany accounts have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zCfYXp261ahl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i><span id="xdx_860_zpYFulhexe5f">Segments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>The Company operates as one operating segment and all assets are located in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_84B_eus-gaap--UseOfEstimates_zqQtde0hG5g5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zo2ZKVnrJDy8">Use of Estimates </span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas subject to significant estimates and judgement include, among others, those related to the fair value of equity awards, accruals for research and development expenses, useful lives of property and equipment, and the valuation allowance on the Company’s deferred tax assets. On an ongoing basis the Company evaluates its estimates and bases its estimates on historical experience and other relevant assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p id="xdx_84C_ecustom--LiquidityPolicyTextBlock_zmPfnoisd6dc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_862_zcPQT30mC2Qb">Liquidity</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has reported recurring losses from operations since its inception and expects to continue to have negative cash flows from operations for the foreseeable future. Historically, the Company’s primary source of funding has been from sales of its securities. The Company’s ability to continue to fund its operations is dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, or strategic opportunities, in order to maintain its operations. This is dependent on a number of factors, including the market demand or liquidity of the Company’s common stock. There is no guarantee that debt, additional equity or other funding will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, the Company would be forced to scale back or terminate its operations or seek to merge with or to be acquired by another company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has limited cash resources, has reported recurring losses from operations since inception, has negative operating cash flows and has not yet received product revenues. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern, and the Company’s current cash resources may not provide sufficient capital to fund operations for at least the next 12 months from the date of the release of these condensed consolidated financial statements. The continuation of the Company as a going concern depends upon the Company’s ability to raise additional capital through an equity offering, debt offering and/or strategic opportunity to fund its operations. There can be no assurance that the Company will be successful in accomplishing these plans in order to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--SignificantAccountingPoliciesTextBlock_zEIUB4E5HTf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86A_zUty3VkhORql">Summary of Significant Accounting Policies</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cash and Cash Equivalents </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash and cash equivalents include unrestricted cash accounts, money market investments and highly liquid investment instruments with original maturity of three months or less at the date of purchase.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than as set forth above, there have been no material changes to the significant accounting policies disclosed in the Company’s 2023 Form 10-K.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z1ml9UHzzpJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2023, the Financial Accounting Standards Board (the “<b>FASB</b>”) issued Accounting Standards Update (“<b>ASU</b>”) 2023-07, “Segment Reporting (Topic 280) – Improvements to Reporting Segment Disclosures” (“<b>ASU 2023-07</b>”), which requires disclosure of incremental segment information on an annual and interim basis. In addition, ASU 2023-07 clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and contains other disclosure requirements. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The enhanced disclosures are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of ASU 2023-07 on its consolidated financial statements and disclosures, but does not expect that it will have a material impact on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740) – Improvements to Income Tax Disclosures” (“ASU 2023-09”), which requires disclosure of specific categories in the rate reconciliation table along with additional information for reconciling items that meet a quantitative threshold, disclosure of disaggregated income taxes paid and modifies other income tax-related disclosures. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-09, but does not expect that it will have a material impact on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_803_eus-gaap--CollaborativeArrangementDisclosureTextBlock_z4VcMKWjqc0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. <span id="xdx_825_zjvuYdlroXii">Collaboration Agreement</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>AgonOx, Inc. (“<b>AgonOx</b>”)</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In February 2021, the Company entered into a clinical co-development collaboration agreement (the “<b>Clinical Co-Development Agreement</b>”) with AgonOx, a private company developing a pipeline of novel immunotherapy drugs targeting key regulators of the immune response to cancer. Under the Clinical Co-Development Agreement, Phio and AgonOx are working to develop a T cell-based therapy using the Company’s lead product candidate, PH-762, and AgonOx’s “double positive” tumor infiltrating lymphocytes (“<b>DP TIL</b>”) technology. Per the terms of the Clinical Co-Development Agreement, the Company agreed to reimburse AgonOx up to $4,000,000 in expenses incurred to conduct a Phase 1 clinical trial of PH-762 treated DP TIL in patients with advanced melanoma and other advanced solid tumors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes its share of costs arising from research and development activities performed by AgonOx in the Company’s condensed consolidated financial statements in the period AgonOx incurs such expense. Phio will be entitled to certain future development milestones and low single-digit sales-based royalty payments from AgonOx’s licensing of its DP TIL technology.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognized approximately $<span id="xdx_90C_ecustom--ExpenseFromContractualObligations_c20240101__20240331__us-gaap--TransactionTypeAxis__custom--ClinicalCoDevelopmentAgreementMember__srt--CounterpartyNameAxis__custom--AgonOxMember_zaX9wt247mg2" title="Expense from contractual obligations">50,000</span> and $<span id="xdx_909_ecustom--ExpenseFromContractualObligations_c20230101__20230331__us-gaap--TransactionTypeAxis__custom--ClinicalCoDevelopmentAgreementMember__srt--CounterpartyNameAxis__custom--AgonOxMember_zhwlmn3UbNT3" title="Expense from contractual obligations">119,000</span> of expense in connection with these efforts during the three months ended March 31, 2024 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 8, 2024, the Company terminated its Clinical Co-Development Agreement with AgonOx, effective immediately. Effective as of the date of the termination, the Clinical Co-Development Agreement and the continuing obligations of the Company and AgonOx thereunder will be terminated in their entirety. The Company will no longer be required to provide financial support for the development costs incurred under the Clinical Co-Development Agreement or be entitled to certain future development milestones and low single-digit sales-based royalty payments from AgonOx’s licensing of its DP TIL technology.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will pay to AgonOx all Company payment obligations that have accrued prior to the termination of the Clinical Co-Development Agreement. The Company intends to pay to AgonOx future fees to be incurred for patients that were treated in the Phase 1 clinical trial as of the date of termination. The Company estimates that such payments to be made to AgonOx will amount to approximately $<span id="xdx_906_eus-gaap--ContractualObligation_iI_c20231231__us-gaap--TransactionTypeAxis__custom--ClinicalCoDevelopmentAgreementMember__srt--CounterpartyNameAxis__custom--AgonOxMember_z3Y66aUDxtAe" title="Contractual obligation">388,000</span>, which primarily relate to the Company’s accrued obligations under the Clinical Co-Development Agreement as of March 31, 2024, as well as future fees to be incurred for patients that were treated in the Phase 1 clinical trial and other miscellaneous costs as of the date of termination. Pursuant to the terms of the Clinical Co-Development Agreement, the Company and AgonOx shall meet and discuss the orderly wind-down of the Phase 1 clinical trial. Each of the Company and AgonOx shall be responsible for its own costs and expenses incurred in connection with the wind-down of the Phase 1 clinical trial. See Item 5. Other Information included elsewhere in this Quarterly Report for further information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> 50000 119000 388000 <p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_zg6RtgyFA25" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>3. <span id="xdx_82B_z6JcfGdlx6ea">Fair Value of Financial Instruments</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company follows the provisions of the Financial Accounting Standards Board (the “<b>FASB</b>”) Accounting Standards Codification (“<b>ASC</b>”) Topic 820, “<i>Fair Value Measurement</i>,” for the Company’s financial assets and liabilities that are re-measured and reported at fair value each reporting period and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 1 – quoted prices in active markets for identical assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2024, the Company categorized its cash equivalents as Level 1 hierarchy as the carrying amounts approximate their fair value due to their short-term nature and market rates of interest. As of December 31, 2023, the Company did not identify any financial instruments required to be presented at fair value.</p> <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_pn3n3_zyBhebEa6OD9" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 93%; margin-right: auto" summary="xdx: Disclosure - Fair Value of Financial Instruments - (Details - Financial instruments at fair value)"> <tr style="vertical-align: bottom"> <td style="text-align: left; text-indent: -12pt; padding-left: 12pt"><span id="xdx_8BC_z9Ejo6Ro6r82" style="display: none">Schedule of financial instruments at fair value</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Quoted Prices</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>In Active Markets</b><br/> <b>(Level 1)</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> <b>Other Significant<br/> Observable Inputs<br/> (Level 2)</b></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unobservable<br/> Inputs<br/> (Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 25%; text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Cash equivalents</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240331__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember_zDNTZUL2Iahd" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Total">6,379</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240331__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqBoMLI7zmn7" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Total">6,379</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_d0_c20240331__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwDWtUek3DJb" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Total">–</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_d0_c20240331__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkLlMEGe4hG" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Total">–</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240331_zblvw7FYOA4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">6,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zx7lasbhjJw9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">6,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_d0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCYVVHz7vEF6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_d0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4bG388dteB8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The carrying amounts of cash, accounts payable and accrued expenses of the Company approximate their fair values due to their short-term nature.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_pn3n3_zyBhebEa6OD9" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 93%; margin-right: auto" summary="xdx: Disclosure - Fair Value of Financial Instruments - (Details - Financial instruments at fair value)"> <tr style="vertical-align: bottom"> <td style="text-align: left; text-indent: -12pt; padding-left: 12pt"><span id="xdx_8BC_z9Ejo6Ro6r82" style="display: none">Schedule of financial instruments at fair value</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Quoted Prices</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>In Active Markets</b><br/> <b>(Level 1)</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> <b>Other Significant<br/> Observable Inputs<br/> (Level 2)</b></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unobservable<br/> Inputs<br/> (Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 25%; text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Cash equivalents</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240331__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember_zDNTZUL2Iahd" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Total">6,379</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240331__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqBoMLI7zmn7" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Total">6,379</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_d0_c20240331__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwDWtUek3DJb" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Total">–</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_d0_c20240331__us-gaap--FairValueByAssetClassAxis__us-gaap--CashAndCashEquivalentsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkLlMEGe4hG" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Total">–</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240331_zblvw7FYOA4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">6,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zx7lasbhjJw9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">6,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_d0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCYVVHz7vEF6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_d0_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4bG388dteB8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 6379000 6379000 0 0 6379000 6379000 0 0 <p id="xdx_808_eus-gaap--LesseeOperatingLeasesTextBlock_zKBZ8lkCqTBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>4. <span id="xdx_82D_zM8e0SzHriEe">Leases</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company’s lease for its corporate headquarters and primary research facility in Marlborough, Massachusetts was for a total of <span id="xdx_90F_eus-gaap--AreaOfRealEstateProperty_iI_usqft_c20240331__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__us-gaap--PropertySubjectToOperatingLeaseMember_zpVxZvIHq8H1" title="Operating lease footage">7,581</span> square feet of office and laboratory space and expired on <span id="xdx_908_eus-gaap--LeaseExpirationDate1_dd_c20240101__20240331__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__us-gaap--PropertySubjectToOperatingLeaseMember_zYbEkYXp3Xcj" title="Lease expiration date">March 31, 2024</span>. The lease agreement did not contain information to determine the borrowing rate implicit in the lease. As such, the Company calculated its incremental borrowing rate based on what the Company would have to pay to borrow on a collateralized basis over the lease term for an amount equal to the remaining lease payments, taking into consideration such assumptions as, but not limited to, the U.S. treasury yield rate and borrowing rates from a creditworthy financial institution using the above lease factors. The Company has continued operations as a primarily remote business with the expiration of the lease, but has contracted a private mailbox with an address of 11 Apex Drive, Suite 300A, PMB 2006, Marlborough, MA 01752 to use as its principal mailing address for SEC and other purposes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company entered into a lease for a laboratory facility located at 17 Briden Street, Worcester, Massachusetts, which commenced on March 1, 2024. The lease covers <span id="xdx_90E_eus-gaap--AreaOfRealEstateProperty_iI_usqft_c20240301__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__us-gaap--PropertySubjectToOperatingLeaseMember_zSyZQxhFhs54" title="Operating lease footage">321</span> square feet of rentable space and expires on <span id="xdx_909_eus-gaap--LeaseExpirationDate1_dd_c20240229__20240301__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__us-gaap--PropertySubjectToOperatingLeaseMember_zPlCawQn2mgl" title="Lease expiration date">September 1, 2024</span>. The total base rent for the premises over the term is expected to be $<span id="xdx_908_eus-gaap--LeaseAndRentalExpense_c20240229__20240301__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__us-gaap--PropertySubjectToOperatingLeaseMember_z5vdYlRhJJb9" title="Total base rent">15,000</span> and the Company has the option to renew for additional 6-month periods. The Company made an accounting policy election under the FASB ASC Topic 824, “<i>Leases</i>” not to recognize leases with a term less than one year on the balance sheet and that do not contain a purchase option. Under the short-term lease election, the Company will recognize the lease payments for the laboratory facility on a straight-line basis over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The lease for the Company’s corporate headquarters represented all of our significant lease obligations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amounts reported in the condensed consolidated balance sheets for the Company’s corporate headquarters classified as an operating lease in which the Company is the lessee and other supplemental balance sheet information is set forth as follows, in thousands, except the lease term (number of years) and discount rate:</p> <table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--SupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_z4qYeT59jghg" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 79%; margin-right: auto" summary="xdx: Disclosure - Leases (Details - Balance sheet lease items)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B2_z0TIBYd5pEKe" style="display: none">Schedule of lease amounts recorded in balance sheet</span></td><td> </td> <td colspan="2" id="xdx_49F_20240331_z0m6QFRxMJi2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49F_20231231_zKyrUJ8D0dxj" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_ecustom--AssetsLesseeAbstract_iB_z8LCAhIhVRci" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 45%; text-align: left; padding-bottom: 2.5pt">Right of use asset</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_d0_c20240331_znGSWhS86Ot1" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Right of use asset">–</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231_zsseoiI3dk2d" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Right of use asset">33</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--LiabilitiesLesseeAbstract_iB_zKVqnLkLwvBj" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeaseLiability_iI_pn3n3_d0_c20240331_zAIXl5JgyMQ2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liability">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--OperatingLeaseLiability_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liability">35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--LeaseTermAndDiscountRateAbstract_iB_zSDWrAuA9zhe" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left">Lease Term and Discount Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average remaining lease term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zZ9DrhboUDU" title="Weighted average remaining lease term">0.25</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20240331_ztqaTFlPyzC7" title="Weighted average discount rate">4.70</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20231231_zdDd3BK2dBUl" title="Weighted average discount rate">4.70</span>%</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operating lease costs included in operating expense were $<span id="xdx_901_eus-gaap--OperatingLeaseCost_pp0p0_c20240101__20240331_zV02Iqiis9Ld" title="Operating lease costs"><span id="xdx_909_eus-gaap--OperatingLeaseCost_pp0p0_c20230101__20230331_zO4lUEEJDPXb" title="Operating lease costs">33,000</span></span> for the three months ended March 31, 2024 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash paid for the amounts included in the measurement of the operating lease liability on the Company’s condensed consolidated balance sheets and included within changes in the lease liability in the operating activities of the Company’s condensed consolidated statements of cash flows was $<span id="xdx_908_eus-gaap--OperatingLeasePayments_pp0p0_c20240101__20240331_zHyZdwsa22N" title="Operating lease payments">35,000</span> and $<span id="xdx_901_eus-gaap--OperatingLeasePayments_pp0p0_c20230101__20230331_zGQJEbRS3vD7" title="Operating lease payments">34,000</span> for the three months ended March 31, 2024 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p> 7581 2024-03-31 321 2024-09-01 15000 <table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--SupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_z4qYeT59jghg" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 79%; margin-right: auto" summary="xdx: Disclosure - Leases (Details - Balance sheet lease items)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B2_z0TIBYd5pEKe" style="display: none">Schedule of lease amounts recorded in balance sheet</span></td><td> </td> <td colspan="2" id="xdx_49F_20240331_z0m6QFRxMJi2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49F_20231231_zKyrUJ8D0dxj" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_ecustom--AssetsLesseeAbstract_iB_z8LCAhIhVRci" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 45%; text-align: left; padding-bottom: 2.5pt">Right of use asset</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_d0_c20240331_znGSWhS86Ot1" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Right of use asset">–</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231_zsseoiI3dk2d" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Right of use asset">33</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--LiabilitiesLesseeAbstract_iB_zKVqnLkLwvBj" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeaseLiability_iI_pn3n3_d0_c20240331_zAIXl5JgyMQ2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liability">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--OperatingLeaseLiability_c20231231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liability">35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--LeaseTermAndDiscountRateAbstract_iB_zSDWrAuA9zhe" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left">Lease Term and Discount Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average remaining lease term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zZ9DrhboUDU" title="Weighted average remaining lease term">0.25</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20240331_ztqaTFlPyzC7" title="Weighted average discount rate">4.70</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20231231_zdDd3BK2dBUl" title="Weighted average discount rate">4.70</span>%</td><td style="text-align: left"> </td></tr> </table> 0 33000 0 35000 P0Y3M 0.0470 0.0470 33000 33000 35000 34000 <p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zrlLBMvuLNkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>5. <span id="xdx_827_zJiOytaQXgJ7">Stockholders’ Equity</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company first assesses warrants that are issued by the Company under the FASB ASC Topic 480, “<i>Distinguishing Liabilities from Equity</i>” (“<b>ASC 480</b>”) to determine whether the warrants are within the scope of ASC 480. If there are no instances outside of the Company’s control that could require cash settlement, the Company then applies and follows the applicable accounting guidance in the FASB ASC Topic 815, “<i>Derivatives and Hedging</i>” (“<b>ASC 815</b>”). Financial instruments are accounted for as either derivative liabilities or equity instruments depending on the specific terms of the agreement. Based on the assessment of the warrants issued by the Company under the guidance in ASC 480 and ASC 815, the warrants issued by the Company have been classified within stockholder’s equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In December 2023, the Company entered into an inducement letter agreement (the “<b>Inducement Letter Agreement</b>”) with certain holders of the Company’s existing warrants to purchase up to an aggregate of <span id="xdx_901_ecustom--AmendedWarrants_c20230101__20231231__us-gaap--SecuritiesFinancingTransactionAxis__custom--December2023FinancingMember_ztbI389jlwU4">2,130,252 </span>shares of the Company’s common stock (the “<b>December 2023 Financing</b>”). Pursuant to the terms of the Inducement Letter Agreement, in the event that the exercise of the existing warrants in the December 2023 Financing would have otherwise caused a holder to exceed the beneficial ownership limitations set forth in the existing warrant, the Company issued the number of shares that would not cause a holder to exceed such beneficial ownership limitation and agreed to hold such balance of shares of common stock in abeyance. Accordingly, an aggregate of <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pip0_c20231231__us-gaap--AwardTypeAxis__custom--AbeyanceSharesMember_zMrKKI4wlNcg">826,370 </span>shares of common stock were held in abeyance (the “<b>Abeyance Shares</b>”) with such Abeyance Shares evidenced through the holder’s existing warrants and which were deemed to be prepaid. The Abeyance Shares were held until notice was received by the holder that the balance of the shares of common stock could be issued in compliance with such beneficial ownership limitations and were exercised pursuant to a notice of exercise from the holder. Until such time, the Abeyance Shares were evidenced through the holder’s existing warrants and have been included in the Company’s table of outstanding warrants below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended March 31, 2024, all of the Abeyance Shares were released and issued. There were <span id="xdx_906_ecustom--WarrantsExercisedShares_do_c20240101__20240331_zkxU8cVO3iM4" title="Warrants exercised shares">no</span> warrant exercises during the three months ended March 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes the Company’s outstanding warrants, all of which are classified as equity instruments, at March 31, 2024:</p> <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zRSJnv14tYoh" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 79%; margin-right: auto" summary="xdx: Disclosure - Stockholders' Equity (Details - Warrants outstanding)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B5_zz8N2IMmyPm1" style="display: none">Schedule of outstanding warrants</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Warrants issued, shares"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Warrants issued, weighted average exercise price"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt">  </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number<br/> of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise Price<br/> Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%; text-align: left">Outstanding at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pip0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zxFSIZoQ6Gt6" style="width: 13%; text-align: right" title="Warrants outstanding, beginning">6,331,288</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePrice_iS_pip0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_z9RPSYsGcOFc" style="width: 13%; text-align: right" title="Warrants outstanding, weighted average exercise price">3.68</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--WarrantsIssuedShares_pip0_d0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_z4eJjcvxSDw6" style="text-align: right" title="Warrants issued, shares">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--WarrantsIssuedWeightedAverageExercisePricePerShare_pip0_d0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zyfgJbhiS3V2" style="text-align: right" title="Warrants issued, weighted average exercise price">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--WarrantsExercisedShare_iN_pip0_di0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zbLsbhnMq5Ji" style="text-align: right" title="Warrants exercised, shares">(826,370</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--WarrantsExercisedWeightedAverageExercisePricePerShare_pip0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zyPnBwtOojia" style="text-align: right" title="Warrants exercised, weighted average exercise price">1.33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--WarrantsExpiredShares_iN_pip0_di0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zXZ3uzr9pnn6" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired, shares">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--WarrantsExpiredWeightedAverageExercisePricePerShare_pip0_d0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zEB4liXRLmlj" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired, weighted average exercise price">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pip0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zu0Bi2OFnm5j" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding">5,504,918</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePrice_iE_pip0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zD8hTb9tPRx8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, weighted average exercise price">4.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> 2130252 826370 0 <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zRSJnv14tYoh" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 79%; margin-right: auto" summary="xdx: Disclosure - Stockholders' Equity (Details - Warrants outstanding)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B5_zz8N2IMmyPm1" style="display: none">Schedule of outstanding warrants</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Warrants issued, shares"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Warrants issued, weighted average exercise price"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt">  </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number<br/> of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise Price<br/> Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%; text-align: left">Outstanding at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pip0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zxFSIZoQ6Gt6" style="width: 13%; text-align: right" title="Warrants outstanding, beginning">6,331,288</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePrice_iS_pip0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_z9RPSYsGcOFc" style="width: 13%; text-align: right" title="Warrants outstanding, weighted average exercise price">3.68</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--WarrantsIssuedShares_pip0_d0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_z4eJjcvxSDw6" style="text-align: right" title="Warrants issued, shares">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--WarrantsIssuedWeightedAverageExercisePricePerShare_pip0_d0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zyfgJbhiS3V2" style="text-align: right" title="Warrants issued, weighted average exercise price">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--WarrantsExercisedShare_iN_pip0_di0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zbLsbhnMq5Ji" style="text-align: right" title="Warrants exercised, shares">(826,370</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--WarrantsExercisedWeightedAverageExercisePricePerShare_pip0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zyPnBwtOojia" style="text-align: right" title="Warrants exercised, weighted average exercise price">1.33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--WarrantsExpiredShares_iN_pip0_di0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zXZ3uzr9pnn6" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired, shares">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--WarrantsExpiredWeightedAverageExercisePricePerShare_pip0_d0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zEB4liXRLmlj" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired, weighted average exercise price">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pip0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zu0Bi2OFnm5j" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding">5,504,918</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePrice_iE_pip0_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zD8hTb9tPRx8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, weighted average exercise price">4.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 6331288 3.68 0 0 826370 1.33 -0 0 5504918 4.03 <p id="xdx_802_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zU383b334AN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6. <span id="xdx_828_z9eH4GEM0vji">Stock-based Compensation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock Units</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted stock units (“<b>RSUs</b>”) are issued under the Company’s 2020 Long-Term Incentive Plan (the “<b>2020 Plan</b>”) or as inducement grants issued outside of the 2020 Plan to new employees. RSUs are generally subject to graded vesting and the satisfaction of certain service requirements. RSUs granted by the Company to employees generally vest annually over <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--CounterpartyNameAxis__custom--EmployeesMember_z5mrfCOkogwj" title="Vesting period">3</span> years after the grant date and over <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--CounterpartyNameAxis__custom--NonEmployeeMembersMember_zHttQLix6ixd" title="Vesting period">1</span> year after the grant date for non-employee members of the Board of Directors. Upon vesting, each outstanding RSU will be settled for one share of the Company’s common stock. Employee RSU recipients may elect to net share settle upon vesting, in which case the Company pays the employee’s income taxes due upon vesting and withholds a number of shares of equal value. The Company does not expect to repurchase shares to satisfy RSU vests. The fair value of the RSUs awarded are based upon the Company’s closing stock price at the grant date and are expensed over the requisite service period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes the activity of the Company’s RSUs for the three months ended March 31, 2024:</p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zGyiNiSBwXL7" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 79%; margin-right: auto" summary="xdx: Disclosure - Stock-based Compensation (Details - RSU activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B6_zTrAARU7G1zc" style="display: none">Summary of RSU activity</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number<br/> of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Grant Date Fair Value<br/> Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%">Unvested units at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKHqhfRPCHxj" style="width: 13%; text-align: right" title="RSU's unvested units, beginning balance">49,683</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmDYjrMn7saj" style="width: 13%; text-align: right" title="RSU beginning balance, price per share">8.32</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pip0_d0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzAGo7NsvKo4" style="text-align: right" title="RSU's granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_d0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7vxm9LGgPve" style="text-align: right" title="RSU's granted, price per share">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pip0_di_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh3B7rHJTMSi" style="text-align: right" title="RSU's vested">(24,198</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7dJ30Pz5QSk" style="text-align: right" title="RSU's vested, price per share">8.80</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pip0_di_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z38M17KwnVBe" style="border-bottom: Black 1pt solid; text-align: right" title="RSU's forfeited">(6,903</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znuEvb0ALU0j" style="border-bottom: Black 1pt solid; text-align: right" title="RSU's forfeited, price per share">10.96</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Unvested units at March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTZcGPiF7p5l" style="border-bottom: Black 2.5pt double; text-align: right" title="RSU's unvested units, ending balance">18,582</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zd0IIWewUbpc" style="border-bottom: Black 2.5pt double; text-align: right" title="RSU ending balance, price per share">6.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zoRkM8zqktV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_do_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRS9IQiKT5H7" title="RSU's granted, price per share">no</span> RSUs granted during the three months ended March 31, 2024. The weighted-average fair value of RSUs granted during the three months ended March 31, 2023 was $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z58X0aqN8DZb" title="RSU's granted, price per share">5.24</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based compensation expense related to RSUs was $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxxcWDsJ1GJ7" title="Share-based compensation expense">26,000</span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0ndq1b0QBmj" title="Share-based compensation expense">111,000</span> for the three months ended March 31, 2024 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate fair value of awards that vested during the three months ended March 31, 2024 and 2023 was $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZ7HVZ7QZvOb" title="Fair value of awards vested">17,000</span> and $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFZiAGQaoIJ8" title="Fair value of awards vested">95,000</span>, respectively, which represents the market value of the Company’s common stock on the date that the RSUs vested.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock Options</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock options are available for issuance under the 2020 Plan or as inducement grants issued outside of the 2020 Plan to new employees. Stock options are generally subject to graded vesting and the satisfaction of service requirements. Stock options granted by the Company to employees generally vest annually over <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--CounterpartyNameAxis__custom--EmployeesMember_za7kH9AtxbHl" title="Vesting period">4</span> years after the grant date and generally vest over <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--CounterpartyNameAxis__custom--BoardOfDirectorsMember_zyujoeXNyojb" title="Vesting period">1</span> year after the grant date for members of the Board of Directors and expire within ten years of grant. Upon the exercise of a stock option, the Company issues new shares and delivers them to the recipient. The Company does not expect to repurchase shares to satisfy stock option exercises.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company uses the Black-Scholes option-pricing model to determine the fair value of all its option grants. The risk-free interest rate used for each grant was based upon the yield on zero-coupon U.S. Treasury securities with a term similar to the expected life of the related option. The Company’s expected stock price volatility assumption is based upon the Company’s own implied volatility. As the Company has limited stock option exercise information, the expected life assumption used for option grants is based upon the simplified method provided for under the FASB ASC Topic 718, “<i>Compensation — Stock Compensation</i>”. The dividend yield assumption is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company did not grant any stock options during the three months ended March 31, 2024 and 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes the activity of the Company’s stock options for the three months ended March 31, 2024:</p> <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z312T2Tni3A6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-based Compensation (Details - Option activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B1_zzitaK7HL3ve" style="display: none">Summary of stock option activity</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number<br/> of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise<br/> Price<br/> Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 49%">Balance at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkT9r9vOOhNk" style="width: 13%; text-align: right" title="Number of shares outstanding, Beginning">10,084</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJcHvOtJ42hb" style="width: 13%; text-align: right" title="Weighted average exercise price per share, Beginning">134.86</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_d0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zU13fi5OEJcg" style="text-align: right" title="Number of shares outstanding, Granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_d0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgLhjtHhgeTb" style="text-align: right" title="Weighted average exercise price per share, Granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_d0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAQioefP7Js4" style="text-align: right" title="Number of shares outstanding, Exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_d0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5cwm2HIOnk5" style="text-align: right" title="Weighted average exercise price per share, Exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pip0_d0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEDCpHWXna26" style="text-align: right" title="Number of shares outstanding, Forfeited">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_d0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgegJDd8uWNb" style="text-align: right" title="Weighted average exercise price per share, Forfeited">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pip0_di_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoIFCBjGNTG4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares outstanding, Expired">(23</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zu7v7wqpkVgd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price per share, Expired">13,541.48</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zilX2HdVfgef" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding, Ending">10,061</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1HkcCfvXz58" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, Ending">104.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_d0_c20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPnFZheqMRs5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Outstanding">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXzBy20zgwD" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding, Exercisable">10,061</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zK1kpJUE5AHe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, Exercisable">104.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_d0_c20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvWilA4s9VYh" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Exercisable">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zioEjj5MVt7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based compensation expense related to stock options for the three months ended March 31, 2024 was $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhLyU8SywIf6" title="Share-based compensation expense">6,000</span>. The Company did <span id="xdx_906_eus-gaap--ShareBasedCompensation_do_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXGzYYzcq3vk" title="Share-based compensation expense">no</span>t have any stock-based compensation expense related to stock options for the three months ended March 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation Expense Related to Equity Awards</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth total stock-based compensation expense for the three months ended March 31, 2024 and 2023, in thousands:</p> <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zLFHhJaw8XO3" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 79%; margin-right: auto" summary="xdx: Disclosure - Stock-based Compensation (Details - Share-based compensation)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B5_zT5uHwHTkK81" style="display: none">Schedule of stock-based compensation expense</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zvpAAVT566y3" style="width: 13%; text-align: right" title="Total stock-based compensation">(11</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5qPz2EhJGsj" style="width: 13%; text-align: right" title="Total stock-based compensation">63</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zuBXUQnvAr23" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">43</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zRLrTJ7HPia2" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">48</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331_zrD0Re1LNdt4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">32</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331_zMer2eiCydOh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> P3Y P1Y <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zGyiNiSBwXL7" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 79%; margin-right: auto" summary="xdx: Disclosure - Stock-based Compensation (Details - RSU activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B6_zTrAARU7G1zc" style="display: none">Summary of RSU activity</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number<br/> of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Grant Date Fair Value<br/> Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%">Unvested units at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKHqhfRPCHxj" style="width: 13%; text-align: right" title="RSU's unvested units, beginning balance">49,683</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmDYjrMn7saj" style="width: 13%; text-align: right" title="RSU beginning balance, price per share">8.32</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pip0_d0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzAGo7NsvKo4" style="text-align: right" title="RSU's granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_d0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7vxm9LGgPve" style="text-align: right" title="RSU's granted, price per share">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pip0_di_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh3B7rHJTMSi" style="text-align: right" title="RSU's vested">(24,198</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7dJ30Pz5QSk" style="text-align: right" title="RSU's vested, price per share">8.80</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pip0_di_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z38M17KwnVBe" style="border-bottom: Black 1pt solid; text-align: right" title="RSU's forfeited">(6,903</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znuEvb0ALU0j" style="border-bottom: Black 1pt solid; text-align: right" title="RSU's forfeited, price per share">10.96</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Unvested units at March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTZcGPiF7p5l" style="border-bottom: Black 2.5pt double; text-align: right" title="RSU's unvested units, ending balance">18,582</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zd0IIWewUbpc" style="border-bottom: Black 2.5pt double; text-align: right" title="RSU ending balance, price per share">6.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 49683 8.32 0 0 24198 8.80 6903 10.96 18582 6.70 0 5.24 26000 111000 17000 95000 P4Y P1Y <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z312T2Tni3A6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-based Compensation (Details - Option activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B1_zzitaK7HL3ve" style="display: none">Summary of stock option activity</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number<br/> of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise<br/> Price<br/> Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 49%">Balance at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkT9r9vOOhNk" style="width: 13%; text-align: right" title="Number of shares outstanding, Beginning">10,084</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJcHvOtJ42hb" style="width: 13%; text-align: right" title="Weighted average exercise price per share, Beginning">134.86</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_d0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zU13fi5OEJcg" style="text-align: right" title="Number of shares outstanding, Granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_d0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgLhjtHhgeTb" style="text-align: right" title="Weighted average exercise price per share, Granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_d0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAQioefP7Js4" style="text-align: right" title="Number of shares outstanding, Exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_d0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5cwm2HIOnk5" style="text-align: right" title="Weighted average exercise price per share, Exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pip0_d0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEDCpHWXna26" style="text-align: right" title="Number of shares outstanding, Forfeited">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_d0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgegJDd8uWNb" style="text-align: right" title="Weighted average exercise price per share, Forfeited">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pip0_di_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoIFCBjGNTG4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares outstanding, Expired">(23</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zu7v7wqpkVgd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price per share, Expired">13,541.48</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zilX2HdVfgef" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding, Ending">10,061</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20240101__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1HkcCfvXz58" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, Ending">104.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_d0_c20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPnFZheqMRs5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Outstanding">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXzBy20zgwD" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding, Exercisable">10,061</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zK1kpJUE5AHe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, Exercisable">104.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_d0_c20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvWilA4s9VYh" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Exercisable">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 10084 134.86 0 0 0 0 0 0 23 13541.48 10061 104.21 0 10061 104.21 0 6000 0 <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zLFHhJaw8XO3" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 79%; margin-right: auto" summary="xdx: Disclosure - Stock-based Compensation (Details - Share-based compensation)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B5_zT5uHwHTkK81" style="display: none">Schedule of stock-based compensation expense</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zvpAAVT566y3" style="width: 13%; text-align: right" title="Total stock-based compensation">(11</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5qPz2EhJGsj" style="width: 13%; text-align: right" title="Total stock-based compensation">63</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zuBXUQnvAr23" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">43</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zRLrTJ7HPia2" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">48</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331_zrD0Re1LNdt4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">32</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331_zMer2eiCydOh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> -11000 63000 43000 48000 32000 111000 <p id="xdx_808_eus-gaap--EarningsPerShareTextBlock_zs1CrPbiUHRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>7. <span id="xdx_825_zrgjNVdMb112">Net Loss per Common Share</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing the Company’s net loss by the weighted average number of common shares outstanding and the impact of the dilutive effect of potential common stock equivalents, except when the inclusion of such potential common stock equivalents would be anti-dilutive. Dilutive potential common stock equivalents primarily consist of stock options, RSUs and warrants. Therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented because the impact of these items is generally anti-dilutive during periods of net loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth the potential common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:</p> <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z340frKVdhla" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 79%; margin-right: auto" summary="xdx: Disclosure - Net Loss per Common Share (Details - Antidilutive shares)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B1_zFGtwZCHT3Qk" style="display: none">Schedule of anti dilutive stock</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" style="width: 13%; text-align: right" title="Antidilutive shares">10,061</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" style="width: 13%; text-align: right" title="Antidilutive shares">177</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unvested RSUs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Antidilutive shares">18,582</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Antidilutive shares">72,755</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zI0P9nRf0588" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">5,504,918</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zfdeHCHDP6f7" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">545,401</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">5,533,561</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">618,333</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z340frKVdhla" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 79%; margin-right: auto" summary="xdx: Disclosure - Net Loss per Common Share (Details - Antidilutive shares)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B1_zFGtwZCHT3Qk" style="display: none">Schedule of anti dilutive stock</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 45%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" style="width: 13%; text-align: right" title="Antidilutive shares">10,061</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" style="width: 13%; text-align: right" title="Antidilutive shares">177</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unvested RSUs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Antidilutive shares">18,582</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Antidilutive shares">72,755</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zI0P9nRf0588" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">5,504,918</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zfdeHCHDP6f7" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">545,401</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">5,533,561</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">618,333</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 10061 177 18582 72755 5504918 545401 5533561 618333